https://asnrt.org/ 2026-07-18 weekly 1.0 https://asnrt.org/about 2026-07-18 monthly 0.8 https://asnrt.org/about/constitution 2026-07-18 yearly 0.5 https://asnrt.org/members 2026-07-18 monthly 0.8 https://asnrt.org/members/coordinators 2026-07-18 monthly 0.7 https://asnrt.org/members/past-presidents 2026-07-18 yearly 0.6 https://asnrt.org/membership 2026-07-18 monthly 0.8 https://asnrt.org/societies 2026-07-18 monthly 0.7 https://asnrt.org/societies/international 2026-07-18 monthly 0.7 https://asnrt.org/education 2026-07-18 weekly 0.8 https://asnrt.org/education/patient 2026-07-18 monthly 0.7 https://asnrt.org/education/nurses 2026-07-18 monthly 0.7 https://asnrt.org/education/doctors 2026-07-18 weekly 0.8 https://asnrt.org/academic 2026-07-18 monthly 0.7 https://asnrt.org/academic/journals 2026-07-18 monthly 0.7 https://asnrt.org/academic/guidelines 2026-07-18 monthly 0.7 https://asnrt.org/events 2026-07-18 weekly 0.8 https://asnrt.org/news 2026-07-18 daily 0.9 https://asnrt.org/news/transplantation 2026-07-18 weekly 0.7 https://asnrt.org/news/dialysis 2026-07-18 weekly 0.7 https://asnrt.org/news/glomerulonephritis 2026-07-18 weekly 0.7 https://asnrt.org/news/ckd 2026-07-18 weekly 0.7 https://asnrt.org/news/aki 2026-07-18 weekly 0.7 https://asnrt.org/news/hypertension-diabetic 2026-07-18 weekly 0.7 https://asnrt.org/news/genetic 2026-07-18 weekly 0.7 https://asnrt.org/news/society-regulatory 2026-07-18 weekly 0.7 https://asnrt.org/news/general 2026-07-18 weekly 0.6 https://asnrt.org/news/ajnt 2026-07-18 weekly 0.8 https://asnrt.org/gallery 2026-07-18 monthly 0.6 https://asnrt.org/contact 2026-07-18 yearly 0.6 https://asnrt.org/donor-card 2026-07-18 monthly 0.7 https://asnrt.org/calculators 2026-07-18 weekly 0.9 https://asnrt.org/journal 2026-07-18 weekly 0.9 https://asnrt.org/journal/cfp 2026-07-18 monthly 0.7 https://asnrt.org/education/patient/transplant 2026-07-18 weekly 0.9 https://asnrt.org/education/patient/transplant/posters 2026-07-18 monthly 0.7 https://asnrt.org/education/patient/transplant/tools/ramadan 2026-07-18 monthly 0.6 https://asnrt.org/education/patient/transplant/tools/drug-food 2026-07-18 monthly 0.6 https://asnrt.org/education/patient/transplant/tools/red-flags 2026-07-18 monthly 0.6 https://asnrt.org/kuwait-transplant 2026-07-18 monthly 0.6 https://asnrt.org/congress 2026-07-18 monthly 0.9 https://asnrt.org/calculators/ckd-epi-creatinine 2026-07-18 monthly 0.7 https://asnrt.org/calculators/ckd-epi-cystatin-c 2026-07-18 monthly 0.7 https://asnrt.org/calculators/cockcroft-gault 2026-07-18 monthly 0.7 https://asnrt.org/calculators/kfre 2026-07-18 monthly 0.7 https://asnrt.org/calculators/fena 2026-07-18 monthly 0.7 https://asnrt.org/calculators/anion-gap 2026-07-18 monthly 0.7 https://asnrt.org/calculators/ttkg 2026-07-18 monthly 0.7 https://asnrt.org/calculators/osmolal-gap 2026-07-18 monthly 0.7 https://asnrt.org/calculators/epts 2026-07-18 monthly 0.7 https://asnrt.org/calculators/kdpi 2026-07-18 monthly 0.7 https://asnrt.org/calculators/banff-classification 2026-07-18 monthly 0.7 https://asnrt.org/calculators/tacrolimus-target 2026-07-18 monthly 0.7 https://asnrt.org/ar 2026-07-18 weekly 1.0 https://asnrt.org/ar/about 2026-07-18 monthly 0.8 https://asnrt.org/ar/members 2026-07-18 monthly 0.8 https://asnrt.org/ar/membership 2026-07-18 monthly 0.8 https://asnrt.org/ar/education 2026-07-18 weekly 0.8 https://asnrt.org/ar/education/patient 2026-07-18 monthly 0.7 https://asnrt.org/ar/events 2026-07-18 weekly 0.8 https://asnrt.org/ar/news 2026-07-18 daily 0.9 https://asnrt.org/ar/contact 2026-07-18 yearly 0.6 https://asnrt.org/ar/donor-card 2026-07-18 monthly 0.7 https://asnrt.org/ar/education/patient/transplant 2026-07-18 weekly 0.9 https://asnrt.org/ar/education/patient/transplant/posters 2026-07-18 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/tools/ramadan 2026-07-18 monthly 0.6 https://asnrt.org/ar/education/patient/transplant/tools/drug-food 2026-07-18 monthly 0.6 https://asnrt.org/ar/education/patient/transplant/tools/red-flags 2026-07-18 monthly 0.6 https://asnrt.org/news/plant-dominant-low-protein-diet-versus-standard-care-in-adults-with-chronic-kidney-disease-stages-3-5-a-randomized-controlled-trial-protocol-mrr8lyx5 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/plant-dominant-low-protein-diet-versus-standard-care-in-adults-with-chronic-kidney-disease-stages-3-5-a-randomized-controlled-trial-protocol-mrr8lyx5 2026-07-19 weekly 0.6 https://asnrt.org/news/vaccinations-to-prevent-infections-in-adults-with-ckd-and-after-kidney-transplantation-a-review-mq99fevr 2026-06-11 weekly 0.7 https://asnrt.org/ar/news/vaccinations-to-prevent-infections-in-adults-with-ckd-and-after-kidney-transplantation-a-review-mq99fevr 2026-06-11 weekly 0.6 https://asnrt.org/news/adding-finerenone-to-sglt2-inhibitors-and-long-term-kidney-outcomes-in-diabetic-kidney-disease-mr4hwwzw 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/adding-finerenone-to-sglt2-inhibitors-and-long-term-kidney-outcomes-in-diabetic-kidney-disease-mr4hwwzw 2026-07-05 weekly 0.6 https://asnrt.org/news/dual-targeting-of-b-cell-compartments-using-belatacept-and-daratumumab-in-highly-sensitized-kidney-transplant-candidates-a-mechanistic-proof-of-concept-desensitization-trial-mptbz41k 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/dual-targeting-of-b-cell-compartments-using-belatacept-and-daratumumab-in-highly-sensitized-kidney-transplant-candidates-a-mechanistic-proof-of-concept-desensitization-trial-mptbz41k 2026-05-31 weekly 0.6 https://asnrt.org/news/pharmacological-blood-pressure-lowering-for-the-prevention-of-cardiovascular-disease-and-death-across-the-full-spectrum-of-chronic-kidney-disease-severity-an-individual-participant-data-meta-analysis-mrugghto 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/pharmacological-blood-pressure-lowering-for-the-prevention-of-cardiovascular-disease-and-death-across-the-full-spectrum-of-chronic-kidney-disease-severity-an-individual-participant-data-meta-analysis-mrugghto 2026-07-21 weekly 0.6 https://asnrt.org/news/pharmacological-blood-pressure-lowering-for-the-prevention-of-cardiovascular-disease-and-death-across-the-full-spectrum-of-chronic-kidney-disease-severity-an-individual-participant-data-meta-analysis-mrugghu0 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/pharmacological-blood-pressure-lowering-for-the-prevention-of-cardiovascular-disease-and-death-across-the-full-spectrum-of-chronic-kidney-disease-severity-an-individual-participant-data-meta-analysis-mrugghu0 2026-07-21 weekly 0.6 https://asnrt.org/news/clazakizumab-in-the-treatment-of-chronic-active-antibody-mediated-kidney-transplant-rejection-results-from-the-imagine-phase-3-randomized-double-blind-placebo-controlled-study-mpzdb4dk 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/clazakizumab-in-the-treatment-of-chronic-active-antibody-mediated-kidney-transplant-rejection-results-from-the-imagine-phase-3-randomized-double-blind-placebo-controlled-study-mpzdb4dk 2026-06-08 weekly 0.6 https://asnrt.org/news/association-between-complete-proteinuria-remission-and-kidney-function-in-the-phase-3-protect-trial-of-sparsentan-in-iga-nephropathy-mru478nv 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/association-between-complete-proteinuria-remission-and-kidney-function-in-the-phase-3-protect-trial-of-sparsentan-in-iga-nephropathy-mru478nv 2026-07-21 weekly 0.6 https://asnrt.org/news/updates-on-kidney-transplantation-from-the-world-transplant-congress-2025-mpzcuje1 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/updates-on-kidney-transplantation-from-the-world-transplant-congress-2025-mpzcuje1 2026-06-08 weekly 0.6 https://asnrt.org/news/cardio-renal-outcomes-in-type-2-diabetes-patients-with-advanced-chronic-kidney-disease-on-sglt2-inhibitors-or-glp-1-receptor-agonists-mq62ow10 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/cardio-renal-outcomes-in-type-2-diabetes-patients-with-advanced-chronic-kidney-disease-on-sglt2-inhibitors-or-glp-1-receptor-agonists-mq62ow10 2026-07-05 weekly 0.6 https://asnrt.org/news/antiproteinuric-effect-of-sparsentan-in-patients-with-genetic-associated-fsgs-enrolled-in-the-duplex-trial-mqdip9vd 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/antiproteinuric-effect-of-sparsentan-in-patients-with-genetic-associated-fsgs-enrolled-in-the-duplex-trial-mqdip9vd 2026-06-14 weekly 0.6 https://asnrt.org/news/immunosuppression-in-older-kidney-transplant-recipients-a-randomized-controlled-trial-optimize-mpzcveoc 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/immunosuppression-in-older-kidney-transplant-recipients-a-randomized-controlled-trial-optimize-mpzcveoc 2026-06-08 weekly 0.6 https://asnrt.org/news/dual-costimulation-blockade-with-the-cd154-specific-fusion-protein-dazodalibep-and-belatacept-for-prophylaxis-of-kidney-allograft-rejection-mqdih70k 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/dual-costimulation-blockade-with-the-cd154-specific-fusion-protein-dazodalibep-and-belatacept-for-prophylaxis-of-kidney-allograft-rejection-mqdih70k 2026-06-14 weekly 0.6 https://asnrt.org/news/endovascular-arteriovenous-fistula-outcomes-and-comparison-with-surgical-arteriovenous-fistula-an-updated-systematic-review-and-meta-analysis-mrr952fu 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/endovascular-arteriovenous-fistula-outcomes-and-comparison-with-surgical-arteriovenous-fistula-an-updated-systematic-review-and-meta-analysis-mrr952fu 2026-07-19 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-obinutuzumab-in-active-systemic-lupus-erythematosus-mpw32bk8 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-obinutuzumab-in-active-systemic-lupus-erythematosus-mpw32bk8 2026-06-08 weekly 0.6 https://asnrt.org/news/finerenone-in-type-1-diabetes-and-chronic-kidney-disease-mru5hbpv 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/finerenone-in-type-1-diabetes-and-chronic-kidney-disease-mru5hbpv 2026-07-21 weekly 0.6 https://asnrt.org/news/finerenone-in-type-1-diabetes-and-chronic-kidney-disease-mru5hbqn 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/finerenone-in-type-1-diabetes-and-chronic-kidney-disease-mru5hbqn 2026-07-21 weekly 0.6 https://asnrt.org/news/sglt2-inhibitors-vs-glp-1-receptor-agonists-for-kidney-outcomes-in-individuals-with-type-2-diabetes-mq2f76lh 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sglt2-inhibitors-vs-glp-1-receptor-agonists-for-kidney-outcomes-in-individuals-with-type-2-diabetes-mq2f76lh 2026-06-08 weekly 0.6 https://asnrt.org/news/meta-analysis-of-randomized-controlled-trials-assessing-the-efficacy-and-safety-of-endothelin-receptor-antagonists-in-ckd-mq3ap1q3 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/meta-analysis-of-randomized-controlled-trials-assessing-the-efficacy-and-safety-of-endothelin-receptor-antagonists-in-ckd-mq3ap1q3 2026-06-08 weekly 0.6 https://asnrt.org/news/a-change-is-gonna-come-to-treatment-of-lupus-nephritis-a-review-mq2dmlvh 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/a-change-is-gonna-come-to-treatment-of-lupus-nephritis-a-review-mq2dmlvh 2026-07-05 weekly 0.6 https://asnrt.org/news/glucagon-like-receptor-agonists-and-next-generation-incretin-based-medications-metabolic-cardiovascular-and-renal-benefits-mrr92j73 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/glucagon-like-receptor-agonists-and-next-generation-incretin-based-medications-metabolic-cardiovascular-and-renal-benefits-mrr92j73 2026-07-19 weekly 0.6 https://asnrt.org/news/quantiferon-cmv-cell-mediated-immunity-to-predict-post-prophylaxis-cmv-disease-in-dr--kidney-transplant-recipients-phase-3-letermovir-vs-valganciclovir-trial-mq9dfz25 2026-06-11 weekly 0.7 https://asnrt.org/ar/news/quantiferon-cmv-cell-mediated-immunity-to-predict-post-prophylaxis-cmv-disease-in-dr--kidney-transplant-recipients-phase-3-letermovir-vs-valganciclovir-trial-mq9dfz25 2026-06-11 weekly 0.6 https://asnrt.org/news/sibeprenlimab-in-iga-nephropathy---interim-analysis-of-a-phase-3-trial-mpw30utw 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sibeprenlimab-in-iga-nephropathy---interim-analysis-of-a-phase-3-trial-mpw30utw 2026-06-08 weekly 0.6 https://asnrt.org/news/a-phase-3-trial-of-atacicept-in-patients-with-iga-nephropathy-mpw309oj 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/a-phase-3-trial-of-atacicept-in-patients-with-iga-nephropathy-mpw309oj 2026-06-08 weekly 0.6 https://asnrt.org/news/news-5 2026-05-27 weekly 0.7 https://asnrt.org/ar/news/news-5 2026-05-27 weekly 0.6 https://asnrt.org/news/replacing-mycophenolate-mofetil-by-everolimus-to-increase-vaccine-immunogenicity-in-kidney-transplant-recipients-a-randomized-controlled-trial-mq99g9cl 2026-06-11 weekly 0.7 https://asnrt.org/ar/news/replacing-mycophenolate-mofetil-by-everolimus-to-increase-vaccine-immunogenicity-in-kidney-transplant-recipients-a-randomized-controlled-trial-mq99g9cl 2026-06-11 weekly 0.6 https://asnrt.org/news/news-2 2026-05-27 weekly 0.7 https://asnrt.org/ar/news/news-2 2026-05-27 weekly 0.6 https://asnrt.org/news/a-conservative-dialysis-strategy-and-kidney-function-recovery-in-dialysis-requiring-acute-kidney-injury-the-liberation-from-acute-dialysis-liberate-d-randomized-clinical-trial-mnsucmsd 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/a-conservative-dialysis-strategy-and-kidney-function-recovery-in-dialysis-requiring-acute-kidney-injury-the-liberation-from-acute-dialysis-liberate-d-randomized-clinical-trial-mnsucmsd 2026-05-28 weekly 0.6 https://asnrt.org/news/tolvaptan-vs-fluid-restriction-in-moderate-profound-hyponatremia-an-open-label-randomized-clinical-trial-mpzcwmij 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/tolvaptan-vs-fluid-restriction-in-moderate-profound-hyponatremia-an-open-label-randomized-clinical-trial-mpzcwmij 2026-06-08 weekly 0.6 https://asnrt.org/news/news-1 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/news-1 2026-07-05 weekly 0.6 https://asnrt.org/news/sglt2-inhibitors-and-kidney-outcomes-by-glomerular-filtration-rate-and-albuminuria-a-meta-analysis-mq9a7de7 2026-06-11 weekly 0.7 https://asnrt.org/ar/news/sglt2-inhibitors-and-kidney-outcomes-by-glomerular-filtration-rate-and-albuminuria-a-meta-analysis-mq9a7de7 2026-06-11 weekly 0.6 https://asnrt.org/news/news-6 2026-05-27 weekly 0.7 https://asnrt.org/ar/news/news-6 2026-05-27 weekly 0.6 https://asnrt.org/news/news-4 2026-05-27 weekly 0.7 https://asnrt.org/ar/news/news-4 2026-05-27 weekly 0.6 https://asnrt.org/news/proteins-and-signalling-pathways-targeted-by-dapagliflozin-and-finerenone-insights-from-dapa-ckd-and-figaro-dkd-mr4hw94c 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/proteins-and-signalling-pathways-targeted-by-dapagliflozin-and-finerenone-insights-from-dapa-ckd-and-figaro-dkd-mr4hw94c 2026-07-05 weekly 0.6 https://asnrt.org/news/improving-the-histologic-detection-of-donor-specific-antibody-negative-antibody-mediated-rejection-in-kidney-transplants-mqdb6bwu 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/improving-the-histologic-detection-of-donor-specific-antibody-negative-antibody-mediated-rejection-in-kidney-transplants-mqdb6bwu 2026-06-14 weekly 0.6 https://asnrt.org/news/contemporary-management-of-advanced-chronic-kidney-disease-an-evidence-based-review-mr4hxjx9 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/contemporary-management-of-advanced-chronic-kidney-disease-an-evidence-based-review-mr4hxjx9 2026-07-05 weekly 0.6 https://asnrt.org/news/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-with-kidney-involvement-2025-update-mr03fpoc 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-with-kidney-involvement-2025-update-mr03fpoc 2026-07-05 weekly 0.6 https://asnrt.org/news/news-3 2026-05-27 weekly 0.7 https://asnrt.org/ar/news/news-3 2026-05-27 weekly 0.6 https://asnrt.org/news/mechanisms-of-diabetic-kidney-disease-and-established-and-emerging-treatments-mru3wmdg 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/mechanisms-of-diabetic-kidney-disease-and-established-and-emerging-treatments-mru3wmdg 2026-07-21 weekly 0.6 https://asnrt.org/news/comparison-of-the-renal-outcomes-of-novel-antidiabetic-agents-in-type-2-diabetes-with-chronic-kidney-disease-a-network-meta-analysis-mq2cx6tb 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/comparison-of-the-renal-outcomes-of-novel-antidiabetic-agents-in-type-2-diabetes-with-chronic-kidney-disease-a-network-meta-analysis-mq2cx6tb 2026-06-08 weekly 0.6 https://asnrt.org/news/prospective-cohort-study-of-obinutuzumab-in-rituximab-resistant-primary-membranous-nephropathy-mr7jamjf 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/prospective-cohort-study-of-obinutuzumab-in-rituximab-resistant-primary-membranous-nephropathy-mr7jamjf 2026-07-05 weekly 0.6 https://asnrt.org/news/a-preventive-care-strategy-to-reduce-moderate-or-severe-acute-kidney-injury-after-major-surgery-bigpak-2-a-multinational-randomised-clinical-trial-mpzd6hod 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/a-preventive-care-strategy-to-reduce-moderate-or-severe-acute-kidney-injury-after-major-surgery-bigpak-2-a-multinational-randomised-clinical-trial-mpzd6hod 2026-06-08 weekly 0.6 https://asnrt.org/news/sodium-bicarbonate-for-severe-metabolic-acidemia-and-acute-kidney-injury-the-bicaricu-2-randomized-clinical-trial-mpzd5fky 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sodium-bicarbonate-for-severe-metabolic-acidemia-and-acute-kidney-injury-the-bicaricu-2-randomized-clinical-trial-mpzd5fky 2026-06-08 weekly 0.6 https://asnrt.org/news/effectiveness-of-sglt2-inhibitors-incretin-based-therapies-and-finerenone-on-cardiorenal-outcomes-a-meta-analysis-and-network-meta-analysis-mpzd3h0e 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/effectiveness-of-sglt2-inhibitors-incretin-based-therapies-and-finerenone-on-cardiorenal-outcomes-a-meta-analysis-and-network-meta-analysis-mpzd3h0e 2026-06-08 weekly 0.6 https://asnrt.org/news/trial-of-pegcetacoplan-in-c3-glomerulopathy-and-immune-complex-mpgn-mptbtbvb 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/trial-of-pegcetacoplan-in-c3-glomerulopathy-and-immune-complex-mpgn-mptbtbvb 2026-05-31 weekly 0.6 https://asnrt.org/news/challenging-clinical-practice-guideline-definitions-in-childhood-nephrotic-syndrome-mpw2rq60 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/challenging-clinical-practice-guideline-definitions-in-childhood-nephrotic-syndrome-mpw2rq60 2026-06-08 weekly 0.6 https://asnrt.org/news/effect-of-glucagon-like-peptide-1-receptor-agonists-on-heart-failure-outcomes-and-cardiovascular-death-across-varying-cardiovascular-kidney-metabolic-comorbidity-mqeo5ivr 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/effect-of-glucagon-like-peptide-1-receptor-agonists-on-heart-failure-outcomes-and-cardiovascular-death-across-varying-cardiovascular-kidney-metabolic-comorbidity-mqeo5ivr 2026-07-05 weekly 0.6 https://asnrt.org/news/donor-derived-cell-free-dna-significantly-improves-rejection-yield-in-kidney-transplant-biopsies-mrk4640i 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/donor-derived-cell-free-dna-significantly-improves-rejection-yield-in-kidney-transplant-biopsies-mrk4640i 2026-07-14 weekly 0.6 https://asnrt.org/news/car-t-cell-therapy-in-nephrology-mrk3szyw 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/car-t-cell-therapy-in-nephrology-mrk3szyw 2026-07-14 weekly 0.6 https://asnrt.org/news/five-years-follow-up-of-imlifidase-desensitized-kidney-transplant-recipients-mrr8gqa1 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/five-years-follow-up-of-imlifidase-desensitized-kidney-transplant-recipients-mrr8gqa1 2026-07-19 weekly 0.6 https://asnrt.org/news/diabetes-mellitus-and-chronic-kidney-disease-the-future-is-being-surpassed-mrlipj37 2026-07-15 weekly 0.7 https://asnrt.org/ar/news/diabetes-mellitus-and-chronic-kidney-disease-the-future-is-being-surpassed-mrlipj37 2026-07-15 weekly 0.6 https://asnrt.org/news/successful-autologous-cd19-car-t-cell-therapy-following-severe-lupus-flare-during-immunosuppressive-washout-in-refractory-lupus-nephritis-mrr938qd 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/successful-autologous-cd19-car-t-cell-therapy-following-severe-lupus-flare-during-immunosuppressive-washout-in-refractory-lupus-nephritis-mrr938qd 2026-07-19 weekly 0.6 https://asnrt.org/news/dapagliflozin-in-patients-hospitalized-for-heart-failure-primary-results-of-the-dapa-act-hf-timi-68-randomized-clinical-trial-and-meta-analysis-of-sglt2-inhibitors-in-patients-hospitalized-for-heart-f-mpzdajtf 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/dapagliflozin-in-patients-hospitalized-for-heart-failure-primary-results-of-the-dapa-act-hf-timi-68-randomized-clinical-trial-and-meta-analysis-of-sglt2-inhibitors-in-patients-hospitalized-for-heart-f-mpzdajtf 2026-06-08 weekly 0.6 https://asnrt.org/news/the-personalized-approach-to-rituximab-treatment-in-membranous-nephropathy-a-multi-center-randomized-controlled-trial-mruj9wpr 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/the-personalized-approach-to-rituximab-treatment-in-membranous-nephropathy-a-multi-center-randomized-controlled-trial-mruj9wpr 2026-07-21 weekly 0.6 https://asnrt.org/news/the-personalized-approach-to-rituximab-treatment-in-membranous-nephropathy-a-multi-center-randomized-controlled-trial-mruj9wor 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/the-personalized-approach-to-rituximab-treatment-in-membranous-nephropathy-a-multi-center-randomized-controlled-trial-mruj9wor 2026-07-21 weekly 0.6 https://asnrt.org/news/the-personalized-approach-to-rituximab-treatment-in-membranous-nephropathy-a-multi-center-randomized-controlled-trial-mruj9wpp 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/the-personalized-approach-to-rituximab-treatment-in-membranous-nephropathy-a-multi-center-randomized-controlled-trial-mruj9wpp 2026-07-21 weekly 0.6 https://asnrt.org/news/comparative-analysis-on-renal-and-cardiovascular-outcomes-of-antidiabetic-treatment-in-chronic-kidney-disease-patients---a-systematic-review-and-network-meta-analysis-mq37oyir 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/comparative-analysis-on-renal-and-cardiovascular-outcomes-of-antidiabetic-treatment-in-chronic-kidney-disease-patients---a-systematic-review-and-network-meta-analysis-mq37oyir 2026-06-08 weekly 0.6 https://asnrt.org/news/impact-of-baseline-glp-1-receptor-agonist-use-on-albuminuria-reduction-and-safety-with-simultaneous-initiation-of-finerenone-and-empagliflozin-in-type-2-diabetes-and-chronic-kidney-disease-confidence--mq3acv6z 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/impact-of-baseline-glp-1-receptor-agonist-use-on-albuminuria-reduction-and-safety-with-simultaneous-initiation-of-finerenone-and-empagliflozin-in-type-2-diabetes-and-chronic-kidney-disease-confidence--mq3acv6z 2026-06-08 weekly 0.6 https://asnrt.org/news/a-multicenter-prospective-cohort-study-evaluating-impact-of-an-active-delisting-strategy-to-enable-kidney-transplantation-in-waitlisted-candidates-with-cpra-999-mppc5fng 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/a-multicenter-prospective-cohort-study-evaluating-impact-of-an-active-delisting-strategy-to-enable-kidney-transplantation-in-waitlisted-candidates-with-cpra-999-mppc5fng 2026-05-31 weekly 0.6 https://asnrt.org/news/infectious-disease-surveillance-and-management-in-clinical-xenotransplantation-experience-with-the-first-human-porcine-kidney-transplant-mrr96587 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/infectious-disease-surveillance-and-management-in-clinical-xenotransplantation-experience-with-the-first-human-porcine-kidney-transplant-mrr96587 2026-07-19 weekly 0.6 https://asnrt.org/news/apol1-kidney-disease-conclusions-from-a-kdigo-controversies-conference-mqdir8xc 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/apol1-kidney-disease-conclusions-from-a-kdigo-controversies-conference-mqdir8xc 2026-06-14 weekly 0.6 https://asnrt.org/news/self-reported-non-adherence-to-immunosuppressive-medication-detected-by-the-baasis-predicts-allograft-rejections-in-kidney-transplant-recipients-mrugkuza 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/self-reported-non-adherence-to-immunosuppressive-medication-detected-by-the-baasis-predicts-allograft-rejections-in-kidney-transplant-recipients-mrugkuza 2026-07-21 weekly 0.6 https://asnrt.org/news/self-reported-non-adherence-to-immunosuppressive-medication-detected-by-the-baasis-predicts-allograft-rejections-in-kidney-transplant-recipients-mrugkuyo 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/self-reported-non-adherence-to-immunosuppressive-medication-detected-by-the-baasis-predicts-allograft-rejections-in-kidney-transplant-recipients-mrugkuyo 2026-07-21 weekly 0.6 https://asnrt.org/news/in-vivo-cd19-car-t-cell-therapy-for-refractory-systemic-lupus-erythematosus-mru3ypv5 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/in-vivo-cd19-car-t-cell-therapy-for-refractory-systemic-lupus-erythematosus-mru3ypv5 2026-07-21 weekly 0.6 https://asnrt.org/news/oral-iptacopan-therapy-in-patients-with-c3-glomerulopathy-a-randomised-double-blind-parallel-group-multicentre-placebo-controlled-phase-3-study-mptbuq6m 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/oral-iptacopan-therapy-in-patients-with-c3-glomerulopathy-a-randomised-double-blind-parallel-group-multicentre-placebo-controlled-phase-3-study-mptbuq6m 2026-05-31 weekly 0.6 https://asnrt.org/news/outcomes-of-solid-organ-transplant-recipients-with-advanced-cancers-receiving-immune-checkpoint-inhibitors-a-systematic-review-and-individual-participant-data-meta-analysis-mq3aghg8 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/outcomes-of-solid-organ-transplant-recipients-with-advanced-cancers-receiving-immune-checkpoint-inhibitors-a-systematic-review-and-individual-participant-data-meta-analysis-mq3aghg8 2026-06-08 weekly 0.6 https://asnrt.org/news/kdigo-iga-nephropathy-guideline-2024-mnviyc6h 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/kdigo-iga-nephropathy-guideline-2024-mnviyc6h 2026-05-28 weekly 0.6 https://asnrt.org/news/executive-summary-of-the-kdigo-2025-clinical-practice-guideline-for-the-management-of-immunoglobulin-a-nephropathy-igan-and-immunoglobulin-a-vasculitis-igav-mo4mumgm 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/executive-summary-of-the-kdigo-2025-clinical-practice-guideline-for-the-management-of-immunoglobulin-a-nephropathy-igan-and-immunoglobulin-a-vasculitis-igav-mo4mumgm 2026-05-31 weekly 0.6 https://asnrt.org/news/randomized-double-blind-placebo-controlled-phase-2a-study-assessing-the-efficacy-and-safety-of-felzartamab-for-iga-nephropathy-mrr8j5d3 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/randomized-double-blind-placebo-controlled-phase-2a-study-assessing-the-efficacy-and-safety-of-felzartamab-for-iga-nephropathy-mrr8j5d3 2026-07-19 weekly 0.6 https://asnrt.org/news/things-we-do-for-no-reason-avoiding-intravenous-iodinated-contrast-material-in-patients-with-acute-kidney-injury-or-chronic-kidney-disease-mru41nv9 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/things-we-do-for-no-reason-avoiding-intravenous-iodinated-contrast-material-in-patients-with-acute-kidney-injury-or-chronic-kidney-disease-mru41nv9 2026-07-21 weekly 0.6 https://asnrt.org/news/bcma-targeted-car-t-cell-therapy-can-effectively-induce-disease-remission-in-refractory-lupus-nephritis-mrliqohc 2026-07-15 weekly 0.7 https://asnrt.org/ar/news/bcma-targeted-car-t-cell-therapy-can-effectively-induce-disease-remission-in-refractory-lupus-nephritis-mrliqohc 2026-07-15 weekly 0.6 https://asnrt.org/news/preventing-chronic-kidney-disease-and-maintaining-kidney-health-conclusions-from-a-kdigo-controversies-conference-mpzcvss0 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/preventing-chronic-kidney-disease-and-maintaining-kidney-health-conclusions-from-a-kdigo-controversies-conference-mpzcvss0 2026-06-08 weekly 0.6 https://asnrt.org/news/immune-checkpoint-inhibitors-associated-acute-kidney-injury-a-systematic-review-and-meta-analysis-of-incidence-kidney-recovery-and-recurrent-risk-mr78i6qa 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/immune-checkpoint-inhibitors-associated-acute-kidney-injury-a-systematic-review-and-meta-analysis-of-incidence-kidney-recovery-and-recurrent-risk-mr78i6qa 2026-07-05 weekly 0.6 https://asnrt.org/news/cardiovascular-and-renal-outcomes-of-dual-combination-therapies-with-glucagon-like-peptide-1-receptor-agonists-and-sodium-glucose-transport-protein-2-inhibitors-a-systematic-review-and-meta-analysis-mq62nd6z 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/cardiovascular-and-renal-outcomes-of-dual-combination-therapies-with-glucagon-like-peptide-1-receptor-agonists-and-sodium-glucose-transport-protein-2-inhibitors-a-systematic-review-and-meta-analysis-mq62nd6z 2026-06-09 weekly 0.6 https://asnrt.org/news/cardio-kidney-outcomes-for-combined-versus-monotherapy-with-finerenone-or-sglt2-inhibitors-in-patients-with-ckd-mpzdbr4a 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/cardio-kidney-outcomes-for-combined-versus-monotherapy-with-finerenone-or-sglt2-inhibitors-in-patients-with-ckd-mpzdbr4a 2026-06-08 weekly 0.6 https://asnrt.org/news/efficacy-of-telitacicept-combined-with-low-dose-mycophenolate-mofetil-in-the-treatment-of-moderate-to-severe-systemic-lupus-erythematosus-mppcz5da 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/efficacy-of-telitacicept-combined-with-low-dose-mycophenolate-mofetil-in-the-treatment-of-moderate-to-severe-systemic-lupus-erythematosus-mppcz5da 2026-05-31 weekly 0.6 https://asnrt.org/news/islet-transplantation-mrr8kgz0 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/islet-transplantation-mrr8kgz0 2026-07-19 weekly 0.6 https://asnrt.org/news/randomized-trial-of-activated-vitamin-d-for-acute-kidney-injury-prevention-in-critically-ill-patients-mqdietzp 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/randomized-trial-of-activated-vitamin-d-for-acute-kidney-injury-prevention-in-critically-ill-patients-mqdietzp 2026-06-14 weekly 0.6 https://asnrt.org/news/benefit-harm-trade-offs-of-intensive-versus-standard-blood-pressure-control-pooled-individual-participant-analysis-mq62lmv9 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/benefit-harm-trade-offs-of-intensive-versus-standard-blood-pressure-control-pooled-individual-participant-analysis-mq62lmv9 2026-06-09 weekly 0.6 https://asnrt.org/news/pilot-randomized-trial-of-dialysis-less-frequently-in-the-elderly-the-dlite-study-mq2cyd2l 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/pilot-randomized-trial-of-dialysis-less-frequently-in-the-elderly-the-dlite-study-mq2cyd2l 2026-06-08 weekly 0.6 https://asnrt.org/news/incremental-peritoneal-dialysis-mru46hc6 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/incremental-peritoneal-dialysis-mru46hc6 2026-07-21 weekly 0.6 https://asnrt.org/news/zigakibart-demonstrates-clinical-safety-and-efficacy-in-a-phase-12-trial-of-healthy-volunteers-and-patients-with-iga-nephropathy-mpzd2tj3 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/zigakibart-demonstrates-clinical-safety-and-efficacy-in-a-phase-12-trial-of-healthy-volunteers-and-patients-with-iga-nephropathy-mpzd2tj3 2026-06-08 weekly 0.6 https://asnrt.org/news/a-randomized-controlled-trial-of-intravenous-immunoglobulin-vs-standard-of-care-for-the-treatment-of-chronic-active-antibody-mediated-rejection-in-kidney-transplant-recipients-vipar-mpzd71qi 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/a-randomized-controlled-trial-of-intravenous-immunoglobulin-vs-standard-of-care-for-the-treatment-of-chronic-active-antibody-mediated-rejection-in-kidney-transplant-recipients-vipar-mpzd71qi 2026-06-08 weekly 0.6 https://asnrt.org/news/2024-american-college-of-rheumatology-acr-guideline-for-the-screening-treatment-and-management-of-lupus-nephritis-moqmoc37 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/2024-american-college-of-rheumatology-acr-guideline-for-the-screening-treatment-and-management-of-lupus-nephritis-moqmoc37 2026-05-31 weekly 0.6 https://asnrt.org/news/cari-guidelines-commentary-on-the-kdigo-clinical-practice-guideline-for-the-management-of-glomerular-diseases-mrk478gh 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/cari-guidelines-commentary-on-the-kdigo-clinical-practice-guideline-for-the-management-of-glomerular-diseases-mrk478gh 2026-07-14 weekly 0.6 https://asnrt.org/news/mortality-on-hemodiafiltration-compared-to-high-flux-hemodialysis-a-brazilian-cohort-study-mq62scax 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/mortality-on-hemodiafiltration-compared-to-high-flux-hemodialysis-a-brazilian-cohort-study-mq62scax 2026-06-09 weekly 0.6 https://asnrt.org/news/women-and-kidney-health-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference-mpzczcc6 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/women-and-kidney-health-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference-mpzczcc6 2026-06-08 weekly 0.6 https://asnrt.org/news/rationale-and-design-of-the-renal-lifecycle-trial-assessing-the-effect-of-dapagliflozin-on-cardiorenal-outcomes-in-severe-chronic-kidney-disease-mru3xb1p 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/rationale-and-design-of-the-renal-lifecycle-trial-assessing-the-effect-of-dapagliflozin-on-cardiorenal-outcomes-in-severe-chronic-kidney-disease-mru3xb1p 2026-07-21 weekly 0.6 https://asnrt.org/news/cardiovascular-kidney-related-and-weight-loss-effects-of-therapeutics-for-type-2-diabetes-a-living-clinical-practice-guideline-mr4hy6ay 2026-07-03 weekly 0.7 https://asnrt.org/ar/news/cardiovascular-kidney-related-and-weight-loss-effects-of-therapeutics-for-type-2-diabetes-a-living-clinical-practice-guideline-mr4hy6ay 2026-07-03 weekly 0.6 https://asnrt.org/news/advancements-in-complement-inhibition-for-pnh-and-primary-complementmediated-thrombotic-microangiopathy-mptbwfmo 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/advancements-in-complement-inhibition-for-pnh-and-primary-complementmediated-thrombotic-microangiopathy-mptbwfmo 2026-05-31 weekly 0.6 https://asnrt.org/news/immunosuppressive-therapy-management-during-sepsis-in-kidney-transplant-recipients-a-prospective-multicenter-study-mq3afk7e 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/immunosuppressive-therapy-management-during-sepsis-in-kidney-transplant-recipients-a-prospective-multicenter-study-mq3afk7e 2026-06-08 weekly 0.6 https://asnrt.org/news/finerenone-with-empagliflozin-in-chronic-kidney-disease-and-type-2-diabetes-confidence-mqdiid9o 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/finerenone-with-empagliflozin-in-chronic-kidney-disease-and-type-2-diabetes-confidence-mqdiid9o 2026-06-14 weekly 0.6 https://asnrt.org/news/effects-of-combined-treatment-with-zibotentan-and-dapagliflozin-compared-to-dapagliflozin-alone-in-patients-with-diabetic-and-non-diabetic-chronic-kidney-disease-mq3aofa3 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/effects-of-combined-treatment-with-zibotentan-and-dapagliflozin-compared-to-dapagliflozin-alone-in-patients-with-diabetic-and-non-diabetic-chronic-kidney-disease-mq3aofa3 2026-07-05 weekly 0.6 https://asnrt.org/news/perioperative-nitric-oxide-conditioning-reduces-acute-kidney-injury-in-cardiac-surgery-patients-with-chronic-kidney-disease-the-defender-trial-a-randomized-controlled-trial-mpzdbg8d 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/perioperative-nitric-oxide-conditioning-reduces-acute-kidney-injury-in-cardiac-surgery-patients-with-chronic-kidney-disease-the-defender-trial-a-randomized-controlled-trial-mpzdbg8d 2026-06-08 weekly 0.6 https://asnrt.org/news/novel-potassium-binders-for-hyperkalemia-and-optimization-of-raas-inhibitor-therapy-in-ckd-or-heart-failure-a-systematic-review-and-meta-analysis-mqdihy5n 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/novel-potassium-binders-for-hyperkalemia-and-optimization-of-raas-inhibitor-therapy-in-ckd-or-heart-failure-a-systematic-review-and-meta-analysis-mqdihy5n 2026-06-14 weekly 0.6 https://asnrt.org/news/haemodiafiltration-versus-high-flux-haemodialysisa-consensus-statement-from-the-eudial-working-group-of-the-era-mq2cz96u 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/haemodiafiltration-versus-high-flux-haemodialysisa-consensus-statement-from-the-eudial-working-group-of-the-era-mq2cz96u 2026-06-08 weekly 0.6 https://asnrt.org/news/validation-of-bcma-cd19-compound-car-t-therapy-in-sle-overlap-syndrome-over-15-year-follow-up-mrugj9dq 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/validation-of-bcma-cd19-compound-car-t-therapy-in-sle-overlap-syndrome-over-15-year-follow-up-mrugj9dq 2026-07-21 weekly 0.6 https://asnrt.org/news/validation-of-bcma-cd19-compound-car-t-therapy-in-sle-overlap-syndrome-over-15-year-follow-up-mrugj9d3 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/validation-of-bcma-cd19-compound-car-t-therapy-in-sle-overlap-syndrome-over-15-year-follow-up-mrugj9d3 2026-07-21 weekly 0.6 https://asnrt.org/news/antibody-mediated-rejection---treatment-standard-mq2dl294 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/antibody-mediated-rejection---treatment-standard-mq2dl294 2026-06-08 weekly 0.6 https://asnrt.org/news/postoperative-20-albumin-infusion-and-acute-kidney-injury-in-high-risk-cardiac-surgery-patients-the-albics-aki-randomized-clinical-trial-mq2fdsyr 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/postoperative-20-albumin-infusion-and-acute-kidney-injury-in-high-risk-cardiac-surgery-patients-the-albics-aki-randomized-clinical-trial-mq2fdsyr 2026-06-08 weekly 0.6 https://asnrt.org/news/belgian-consensus-guidelines-within-eurotransplant-on-imlifidase-enabled-deceased-donor-kidney-transplantation-in-highly-sensitized-patients-mppc4xbs 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/belgian-consensus-guidelines-within-eurotransplant-on-imlifidase-enabled-deceased-donor-kidney-transplantation-in-highly-sensitized-patients-mppc4xbs 2026-05-31 weekly 0.6 https://asnrt.org/news/clinical-practice-guidelines-for-acute-kidney-injury-a-systematic-review-of-the-methodological-quality-moh27paw 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/clinical-practice-guidelines-for-acute-kidney-injury-a-systematic-review-of-the-methodological-quality-moh27paw 2026-05-31 weekly 0.6 https://asnrt.org/news/anti-cd38-daratumumab-treatment-of-chronic-active-antibody-mediated-kidney-allograft-rejection-mpw2zc7o 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/anti-cd38-daratumumab-treatment-of-chronic-active-antibody-mediated-kidney-allograft-rejection-mpw2zc7o 2026-06-08 weekly 0.6 https://asnrt.org/news/outcomes-after-kidney-transplantation-in-antineutrophil-cytoplasmic-autoantibody-associated-renal-vasculitis-mrugmpfz 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/outcomes-after-kidney-transplantation-in-antineutrophil-cytoplasmic-autoantibody-associated-renal-vasculitis-mrugmpfz 2026-07-21 weekly 0.6 https://asnrt.org/news/pregnancy-and-long-term-kidney-function-in-ckd-a-systematic-review-and-meta-analysis-mpzcyrr3 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/pregnancy-and-long-term-kidney-function-in-ckd-a-systematic-review-and-meta-analysis-mpzcyrr3 2026-06-08 weekly 0.6 https://asnrt.org/news/long-term-mortality-and-technique-survival-in-peritoneal-dialysis-patients-a-25-year-retrospective-analysis-in-a-single-center-mrr94hsj 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/long-term-mortality-and-technique-survival-in-peritoneal-dialysis-patients-a-25-year-retrospective-analysis-in-a-single-center-mrr94hsj 2026-07-19 weekly 0.6 https://asnrt.org/news/systematic-review-and-network-meta-analysis-of-initial-treatments-for-lupus-nephritis-mpw31ym7 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/systematic-review-and-network-meta-analysis-of-initial-treatments-for-lupus-nephritis-mpw31ym7 2026-06-08 weekly 0.6 https://asnrt.org/news/intensive-systolic-blood-pressure-reduction-and-kidney-and-cardiovascular-outcomes-crhcp-secondary-analysis-mq62kqgq 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/intensive-systolic-blood-pressure-reduction-and-kidney-and-cardiovascular-outcomes-crhcp-secondary-analysis-mq62kqgq 2026-06-09 weekly 0.6 https://asnrt.org/news/induction-of-immune-tolerance-in-living-related-human-leukocyte-antigen-matched-kidney-transplantation-a-phase-3-randomized-clinical-trial-mpzd1lag 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/induction-of-immune-tolerance-in-living-related-human-leukocyte-antigen-matched-kidney-transplantation-a-phase-3-randomized-clinical-trial-mpzd1lag 2026-06-08 weekly 0.6 https://asnrt.org/news/association-of-hospital-level-continuous-kidney-replacement-therapy-use-and-mortality-in-critically-ill-patients-with-acute-kidney-injury-mqdifa3g 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/association-of-hospital-level-continuous-kidney-replacement-therapy-use-and-mortality-in-critically-ill-patients-with-acute-kidney-injury-mqdifa3g 2026-06-14 weekly 0.6 https://asnrt.org/news/obesity-related-glomerulosclerosis-how-adiposity-damages-the-kidneys-mrk627g2 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/obesity-related-glomerulosclerosis-how-adiposity-damages-the-kidneys-mrk627g2 2026-07-14 weekly 0.6 https://asnrt.org/news/kdigo-2024-clinical-practice-guideline-on-evaluation-and-management-of-chronic-kidney-disease-a-primer-on-what-pharmacists-need-to-know-motvu6ie 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/kdigo-2024-clinical-practice-guideline-on-evaluation-and-management-of-chronic-kidney-disease-a-primer-on-what-pharmacists-need-to-know-motvu6ie 2026-05-28 weekly 0.6 https://asnrt.org/news/liberal-fluid-intake-versus-fluid-restriction-in-chronic-heart-failure-a-randomized-clinical-trial-mq2fckmf 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/liberal-fluid-intake-versus-fluid-restriction-in-chronic-heart-failure-a-randomized-clinical-trial-mq2fckmf 2026-06-08 weekly 0.6 https://asnrt.org/news/the-efficacy-and-safety-of-continuous-veno-venous-hemodiafiltration-with-high-cutoff-membrane-versus-high-flux-membrane-in-septic-acute-kidney-injury-a-randomized-controlled-study-mrk3on2p 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/the-efficacy-and-safety-of-continuous-veno-venous-hemodiafiltration-with-high-cutoff-membrane-versus-high-flux-membrane-in-septic-acute-kidney-injury-a-randomized-controlled-study-mrk3on2p 2026-07-14 weekly 0.6 https://asnrt.org/news/safety-and-efficacy-of-sirolimus-combined-with-cyclosporine-in-primary-membranous-nephropathy-a-randomized-controlled-trial-mpzdczbf 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/safety-and-efficacy-of-sirolimus-combined-with-cyclosporine-in-primary-membranous-nephropathy-a-randomized-controlled-trial-mpzdczbf 2026-06-08 weekly 0.6 https://asnrt.org/news/diagnosis-management-and-treatment-of-the-alport-syndrome---2024-guideline-on-behalf-of-erknet-era-and-espn-mpw31c4r 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/diagnosis-management-and-treatment-of-the-alport-syndrome---2024-guideline-on-behalf-of-erknet-era-and-espn-mpw31c4r 2026-06-08 weekly 0.6 https://asnrt.org/news/oral-semaglutide-and-cardiovascular-outcomes-in-high-risk-type-2-diabetes-mpw2xgw8 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/oral-semaglutide-and-cardiovascular-outcomes-in-high-risk-type-2-diabetes-mpw2xgw8 2026-07-05 weekly 0.6 https://asnrt.org/news/long-term-outcomes-of-rituximab-treatment-for-primary-membranous-nephropathy-mnrbhtmi 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/long-term-outcomes-of-rituximab-treatment-for-primary-membranous-nephropathy-mnrbhtmi 2026-05-31 weekly 0.6 https://asnrt.org/news/long-term-outcome-of-adult-patients-with-membranous-nephropathy-treated-with-rituximab-mr7j9x0h 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/long-term-outcome-of-adult-patients-with-membranous-nephropathy-treated-with-rituximab-mr7j9x0h 2026-07-05 weekly 0.6 https://asnrt.org/news/tacrolimus-or-mycophenolate-mofetil-for-frequently-relapsing-or-steroid-dependent-nephrotic-syndrome-a-randomized-clinical-trial-mrugnhqr 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/tacrolimus-or-mycophenolate-mofetil-for-frequently-relapsing-or-steroid-dependent-nephrotic-syndrome-a-randomized-clinical-trial-mrugnhqr 2026-07-21 weekly 0.6 https://asnrt.org/news/finerenone-reduces-new-onset-atrial-fibrillation-across-the-spectrum-of-cardio-kidney-metabolic-syndrome-the-fine-heart-pooled-analysis-mol61gnb 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/finerenone-reduces-new-onset-atrial-fibrillation-across-the-spectrum-of-cardio-kidney-metabolic-syndrome-the-fine-heart-pooled-analysis-mol61gnb 2026-05-31 weekly 0.6 https://asnrt.org/news/high-volume-hemodiafiltration-expanding-the-evidence-beyond-randomized-trials-a-critical-perspective-on-the-2025-eudial-consensus-mrk3sgyr 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/high-volume-hemodiafiltration-expanding-the-evidence-beyond-randomized-trials-a-critical-perspective-on-the-2025-eudial-consensus-mrk3sgyr 2026-07-14 weekly 0.6 https://asnrt.org/news/cvot-summit-report-2024-new-cardiovascular-kidney-and-metabolic-outcomes-mqj7qxf0 2026-06-18 weekly 0.7 https://asnrt.org/ar/news/cvot-summit-report-2024-new-cardiovascular-kidney-and-metabolic-outcomes-mqj7qxf0 2026-06-18 weekly 0.6 https://asnrt.org/news/alport-syndrome-an-update-mrk3qsnf 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/alport-syndrome-an-update-mrk3qsnf 2026-07-14 weekly 0.6 https://asnrt.org/news/kdigo-2025-clinical-practice-guideline-for-the-management-of-nephrotic-syndrome-in-children-mrugp32m 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/kdigo-2025-clinical-practice-guideline-for-the-management-of-nephrotic-syndrome-in-children-mrugp32m 2026-07-21 weekly 0.6 https://asnrt.org/news/sglt2-inhibitors-and-glp-1-receptor-agonists-in-diabetic-kidney-disease-evolving-evidence-and-clinical-application-mq37pbvf 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sglt2-inhibitors-and-glp-1-receptor-agonists-in-diabetic-kidney-disease-evolving-evidence-and-clinical-application-mq37pbvf 2026-06-08 weekly 0.6 https://asnrt.org/news/sodium-zirconium-cyclosilicate-for-mras-optimization-in-hfref-lessons-learned-from-the-realize-k-trial-mpw2rcyo 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sodium-zirconium-cyclosilicate-for-mras-optimization-in-hfref-lessons-learned-from-the-realize-k-trial-mpw2rcyo 2026-06-08 weekly 0.6 https://asnrt.org/news/glp-1-receptor-agonists-in-kidney-transplant-recipients-with-pre-existing-diabetes-a-retrospective-cohort-study-mq2fbku1 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/glp-1-receptor-agonists-in-kidney-transplant-recipients-with-pre-existing-diabetes-a-retrospective-cohort-study-mq2fbku1 2026-06-08 weekly 0.6 https://asnrt.org/news/risk-directed-management-of-chronic-kidney-disease-mpzcw6h3 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/risk-directed-management-of-chronic-kidney-disease-mpzcw6h3 2026-06-08 weekly 0.6 https://asnrt.org/news/cardiovascular-and-kidney-outcomes-and-mortality-with-long-acting-injectable-and-oral-glucagon-like-peptide-1-receptor-agonists-in-individuals-with-type-2-diabetes-a-systematic-review-and-meta-analysi-mqdium1p 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/cardiovascular-and-kidney-outcomes-and-mortality-with-long-acting-injectable-and-oral-glucagon-like-peptide-1-receptor-agonists-in-individuals-with-type-2-diabetes-a-systematic-review-and-meta-analysi-mqdium1p 2026-06-14 weekly 0.6 https://asnrt.org/news/kidney-and-cardiovascular-outcomes-among-patients-with-ckd-receiving-glp-1-receptor-agonists-a-systematic-review-and-meta-analysis-of-randomized-trials-mqeo3j5o 2026-06-15 weekly 0.7 https://asnrt.org/ar/news/kidney-and-cardiovascular-outcomes-among-patients-with-ckd-receiving-glp-1-receptor-agonists-a-systematic-review-and-meta-analysis-of-randomized-trials-mqeo3j5o 2026-06-15 weekly 0.6 https://asnrt.org/news/mapping-the-evolution-of-solid-organ-xenotransplantation-researcha-systematic-review-mru44a7c 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/mapping-the-evolution-of-solid-organ-xenotransplantation-researcha-systematic-review-mru44a7c 2026-07-21 weekly 0.6 https://asnrt.org/news/effect-of-felzartamab-on-the-molecular-phenotype-of-antibody-mediated-rejection-in-kidney-transplant-biopsies-mpzdcmox 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/effect-of-felzartamab-on-the-molecular-phenotype-of-antibody-mediated-rejection-in-kidney-transplant-biopsies-mpzdcmox 2026-06-08 weekly 0.6 https://asnrt.org/news/evaluation-and-management-of-chronic-kidney-disease-synopsis-of-the-kidney-disease-improving-global-outcomes-2024-clinical-practice-guideline-mrlinyy2 2026-07-15 weekly 0.7 https://asnrt.org/ar/news/evaluation-and-management-of-chronic-kidney-disease-synopsis-of-the-kidney-disease-improving-global-outcomes-2024-clinical-practice-guideline-mrlinyy2 2026-07-15 weekly 0.6 https://asnrt.org/news/growth-and-puberty-development-in-pediatric-chronic-kidney-disease-patients-role-of-dialysis-and-transplantation-mrr90grx 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/growth-and-puberty-development-in-pediatric-chronic-kidney-disease-patients-role-of-dialysis-and-transplantation-mrr90grx 2026-07-19 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-obinutuzumab-in-active-lupus-nephritis-mptbsudl 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-obinutuzumab-in-active-lupus-nephritis-mptbsudl 2026-05-31 weekly 0.6 https://asnrt.org/news/high-volume-hemodiafiltration-versus-high-flux-hemodialysis-a-narrative-review-for-the-clinician-mrk3plnm 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/high-volume-hemodiafiltration-versus-high-flux-hemodialysis-a-narrative-review-for-the-clinician-mrk3plnm 2026-07-14 weekly 0.6 https://asnrt.org/news/treatment-of-patients-with-iga-nephropathy-a-call-for-a-new-paradigm-mppcuj2f 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/treatment-of-patients-with-iga-nephropathy-a-call-for-a-new-paradigm-mppcuj2f 2026-05-31 weekly 0.6 https://asnrt.org/news/treatment-of-autosomal-dominant-polycystic-kidney-disease-mqnn2dae 2026-06-21 weekly 0.7 https://asnrt.org/ar/news/treatment-of-autosomal-dominant-polycystic-kidney-disease-mqnn2dae 2026-06-21 weekly 0.6 https://asnrt.org/news/time-to-renal-replacement-therapy-initiation-in-critically-ill-patients-with-acute-kidney-injury-a-secondary-analysis-of-the-starrt-aki-trial-mqdig5kh 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/time-to-renal-replacement-therapy-initiation-in-critically-ill-patients-with-acute-kidney-injury-a-secondary-analysis-of-the-starrt-aki-trial-mqdig5kh 2026-06-14 weekly 0.6 https://asnrt.org/news/bk-polyomavirus-associated-nephropathy---diagnostic-and-treatment-standard-mq3ah59r 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/bk-polyomavirus-associated-nephropathy---diagnostic-and-treatment-standard-mq3ah59r 2026-06-08 weekly 0.6 https://asnrt.org/news/belatacept-versus-tacrolimus-for-kidney-transplant-recipients-of-deceased-donors-with-acute-kidney-injury-us-national-database-study-mq2fjvy2 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/belatacept-versus-tacrolimus-for-kidney-transplant-recipients-of-deceased-donors-with-acute-kidney-injury-us-national-database-study-mq2fjvy2 2026-06-08 weekly 0.6 https://asnrt.org/news/timing-of-continuous-renal-replacement-therapy-in-acute-kidney-injury-a-meta-analysis-of-randomized-trials-mq3aputl 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/timing-of-continuous-renal-replacement-therapy-in-acute-kidney-injury-a-meta-analysis-of-randomized-trials-mq3aputl 2026-06-08 weekly 0.6 https://asnrt.org/news/cardiovascular-outcomes-with-semaglutide-by-severity-of-chronic-kidney-disease-in-type-2-diabetes-the-flow-trial-mrk46q8v 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/cardiovascular-outcomes-with-semaglutide-by-severity-of-chronic-kidney-disease-in-type-2-diabetes-the-flow-trial-mrk46q8v 2026-07-14 weekly 0.6 https://asnrt.org/news/maintenance-immunosuppression-in-kidney-transplantation-a-review-of-the-current-status-and-future-directions-mqdb4o02 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/maintenance-immunosuppression-in-kidney-transplantation-a-review-of-the-current-status-and-future-directions-mqdb4o02 2026-06-14 weekly 0.6 https://asnrt.org/news/advances-in-the-diagnosis-of-early-biomarkers-for-acute-kidney-injury-a-literature-review-mrr8in3g 2026-07-19 weekly 0.7 https://asnrt.org/ar/news/advances-in-the-diagnosis-of-early-biomarkers-for-acute-kidney-injury-a-literature-review-mrr8in3g 2026-07-19 weekly 0.6 https://asnrt.org/news/anatomy-of-endovascular-arteriovenous-fistula-creation-mrugh25f 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/anatomy-of-endovascular-arteriovenous-fistula-creation-mrugh25f 2026-07-21 weekly 0.6 https://asnrt.org/news/anatomy-of-endovascular-arteriovenous-fistula-creation-mrugh26f 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/anatomy-of-endovascular-arteriovenous-fistula-creation-mrugh26f 2026-07-21 weekly 0.6 https://asnrt.org/news/safety-and-efficacy-of-avacopan-in-patients-with-complement-3-glomerulopathy-mptbq4r3 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/safety-and-efficacy-of-avacopan-in-patients-with-complement-3-glomerulopathy-mptbq4r3 2026-07-05 weekly 0.6 https://asnrt.org/news/chronic-kidney-disease-mineral-and-bone-disorder-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference-moh2bcy3 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/chronic-kidney-disease-mineral-and-bone-disorder-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference-moh2bcy3 2026-05-31 weekly 0.6 https://asnrt.org/news/tirzepatide-associated-with-reduced-albuminuria-in-participants-with-type-2-diabetes-pooled-post-hoc-analysis-from-the-randomized-active--and-placebo-controlled-surpass-1-5-clinical-trials-mpzda0r4 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/tirzepatide-associated-with-reduced-albuminuria-in-participants-with-type-2-diabetes-pooled-post-hoc-analysis-from-the-randomized-active--and-placebo-controlled-surpass-1-5-clinical-trials-mpzda0r4 2026-06-08 weekly 0.6 https://asnrt.org/news/association-of-glucagon-like-peptide-1-receptor-agonists-with-cardiovascular-and-kidney-outcomes-in-type-2-diabetic-kidney-transplant-recipients-mqdisg0u 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/association-of-glucagon-like-peptide-1-receptor-agonists-with-cardiovascular-and-kidney-outcomes-in-type-2-diabetic-kidney-transplant-recipients-mqdisg0u 2026-06-14 weekly 0.6 https://asnrt.org/news/long-term-effects-of-empagliflozin-in-patients-with-chronic-kidney-disease-mnsuhnlk 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/long-term-effects-of-empagliflozin-in-patients-with-chronic-kidney-disease-mnsuhnlk 2026-05-31 weekly 0.6 https://asnrt.org/news/glucagon-like-peptide-1-glp-1-receptor-agonists-for-people-with-chronic-kidney-disease-and-diabetes-mpcb8csp 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/glucagon-like-peptide-1-glp-1-receptor-agonists-for-people-with-chronic-kidney-disease-and-diabetes-mpcb8csp 2026-05-31 weekly 0.6 https://asnrt.org/news/effect-of-restrictive-fluid-resuscitation-on-severe-acute-kidney-injury-in-septic-shock-a-systematic-review-and-meta-analysis-mrlisfht 2026-07-15 weekly 0.7 https://asnrt.org/ar/news/effect-of-restrictive-fluid-resuscitation-on-severe-acute-kidney-injury-in-septic-shock-a-systematic-review-and-meta-analysis-mrlisfht 2026-07-15 weekly 0.6 https://asnrt.org/news/atrasentan-in-patients-with-iga-nephropathy-mrk3zh9w 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/atrasentan-in-patients-with-iga-nephropathy-mrk3zh9w 2026-07-14 weekly 0.6 https://asnrt.org/news/alternative-complement-pathway-inhibition-with-iptacopan-in-iga-nephropathy-mr78hka4 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/alternative-complement-pathway-inhibition-with-iptacopan-in-iga-nephropathy-mr78hka4 2026-07-05 weekly 0.6 https://asnrt.org/news/atrasentan-in-patients-with-iga-nephropathy-mnrbf2i9 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/atrasentan-in-patients-with-iga-nephropathy-mnrbf2i9 2026-05-31 weekly 0.6 https://asnrt.org/news/combination-therapy-as-a-new-standard-of-care-in-diabetic-and-non-diabetic-chronic-kidney-disease-mpzcu1nh 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/combination-therapy-as-a-new-standard-of-care-in-diabetic-and-non-diabetic-chronic-kidney-disease-mpzcu1nh 2026-06-08 weekly 0.6 https://asnrt.org/news/combination-therapy-an-upcoming-paradigm-to-improve-kidney-and-cardiovascular-outcomes-in-chronic-kidney-disease-mq2djqtv 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/combination-therapy-an-upcoming-paradigm-to-improve-kidney-and-cardiovascular-outcomes-in-chronic-kidney-disease-mq2djqtv 2026-06-08 weekly 0.6 https://asnrt.org/news/design-and-baseline-characteristics-of-the-finerenone-in-addition-to-standard-of-care-on-the-progression-of-kidney-disease-in-patients-with-non-diabetic-chronic-kidney-disease-find-ckd-randomized-tria-mrugi2r3 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/design-and-baseline-characteristics-of-the-finerenone-in-addition-to-standard-of-care-on-the-progression-of-kidney-disease-in-patients-with-non-diabetic-chronic-kidney-disease-find-ckd-randomized-tria-mrugi2r3 2026-07-21 weekly 0.6 https://asnrt.org/news/design-and-baseline-characteristics-of-the-finerenone-in-addition-to-standard-of-care-on-the-progression-of-kidney-disease-in-patients-with-non-diabetic-chronic-kidney-disease-find-ckd-randomized-tria-mrugi2r1 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/design-and-baseline-characteristics-of-the-finerenone-in-addition-to-standard-of-care-on-the-progression-of-kidney-disease-in-patients-with-non-diabetic-chronic-kidney-disease-find-ckd-randomized-tria-mrugi2r1 2026-07-21 weekly 0.6 https://asnrt.org/news/kdoqi-us-commentary-on-the-kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of-ckd-mo32ne4w 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/kdoqi-us-commentary-on-the-kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of-ckd-mo32ne4w 2026-05-31 weekly 0.6 https://asnrt.org/news/2024-update-in-heart-failure-mos2dmq2 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/2024-update-in-heart-failure-mos2dmq2 2026-05-31 weekly 0.6 https://asnrt.org/news/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-executive-summary-mpw31mlz 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-executive-summary-mpw31mlz 2026-06-08 weekly 0.6 https://asnrt.org/news/chronic-kidney-disease-mo859ery 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/chronic-kidney-disease-mo859ery 2026-05-31 weekly 0.6 https://asnrt.org/news/finerenone-and-kidney-outcomes-in-patients-with-heart-failure-the-finearts-hf-trial-mphx0s33 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/finerenone-and-kidney-outcomes-in-patients-with-heart-failure-the-finearts-hf-trial-mphx0s33 2026-05-31 weekly 0.6 https://asnrt.org/news/desensitization-with-imlifidase-for-hla-incompatible-deceased-donor-kidney-transplantation-a-delphi-international-expert-consensus-mrk645xu 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/desensitization-with-imlifidase-for-hla-incompatible-deceased-donor-kidney-transplantation-a-delphi-international-expert-consensus-mrk645xu 2026-07-14 weekly 0.6 https://asnrt.org/news/small-molecule-apol1-inhibitors-as-a-precision-medicine-approach-for-apol1-mediated-kidney-disease-mpu8saxb 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/small-molecule-apol1-inhibitors-as-a-precision-medicine-approach-for-apol1-mediated-kidney-disease-mpu8saxb 2026-05-31 weekly 0.6 https://asnrt.org/news/effects-of-glp-1-receptor-agonists-on-kidney-and-cardiovascular-disease-outcomes-a-meta-analysis-of-randomised-controlled-trials-mqdit3hz 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/effects-of-glp-1-receptor-agonists-on-kidney-and-cardiovascular-disease-outcomes-a-meta-analysis-of-randomised-controlled-trials-mqdit3hz 2026-06-14 weekly 0.6 https://asnrt.org/news/diagnosis-and-management-of-immune-checkpoint-inhibitor-associated-nephrotoxicity-a-position-statement-from-the-american-society-of-onco-nephrology-mr78leno 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/diagnosis-and-management-of-immune-checkpoint-inhibitor-associated-nephrotoxicity-a-position-statement-from-the-american-society-of-onco-nephrology-mr78leno 2026-07-05 weekly 0.6 https://asnrt.org/news/diagnosis-and-management-of-immune-checkpoint-inhibitor-associated-acute-kidney-injury-mptbvp66 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/diagnosis-and-management-of-immune-checkpoint-inhibitor-associated-acute-kidney-injury-mptbvp66 2026-05-31 weekly 0.6 https://asnrt.org/news/empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid-kidney-stones-a-randomized-phase-2-trial-mpw2woft 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid-kidney-stones-a-randomized-phase-2-trial-mpw2woft 2026-06-08 weekly 0.6 https://asnrt.org/news/obinutuzumab-may-be-an-effective-and-safe-option-for-adult-minimal-change-disease-and-focal-segmental-glomerulosclerosis-patients-after-multitarget-therapy-including-rituximab-mp2u1gw9 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/obinutuzumab-may-be-an-effective-and-safe-option-for-adult-minimal-change-disease-and-focal-segmental-glomerulosclerosis-patients-after-multitarget-therapy-including-rituximab-mp2u1gw9 2026-05-31 weekly 0.6 https://asnrt.org/news/the-pathogenesis-of-iga-nephropathy-and-implications-for-treatment-mrugjsme 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/the-pathogenesis-of-iga-nephropathy-and-implications-for-treatment-mrugjsme 2026-07-21 weekly 0.6 https://asnrt.org/news/anti-hla-serological-response-to-cd38-targeting-desensitization-therapy-is-challenged-by-peripheral-memory-b-cells-in-highly-sensitized-kidney-transplant-candidates-mptbxu9f 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/anti-hla-serological-response-to-cd38-targeting-desensitization-therapy-is-challenged-by-peripheral-memory-b-cells-in-highly-sensitized-kidney-transplant-candidates-mptbxu9f 2026-05-31 weekly 0.6 https://asnrt.org/news/correction-rates-and-clinical-outcomes-in-hospitalized-adults-with-severe-hyponatremia-a-systematic-review-and-meta-analysis-mpzd0i0v 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/correction-rates-and-clinical-outcomes-in-hospitalized-adults-with-severe-hyponatremia-a-systematic-review-and-meta-analysis-mpzd0i0v 2026-06-08 weekly 0.6 https://asnrt.org/news/mini-review-banff-2022-updated-classification-of-renal-allograft-pathology-mrk3rorv 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/mini-review-banff-2022-updated-classification-of-renal-allograft-pathology-mrk3rorv 2026-07-14 weekly 0.6 https://asnrt.org/news/sodium-glucose-cotransporter-2-inhibitors-and-kidney-outcomes-across-the-spectrum-of-kidney-disease-a-systematic-review-and-meta-analysis-mrlirfee 2026-07-15 weekly 0.7 https://asnrt.org/ar/news/sodium-glucose-cotransporter-2-inhibitors-and-kidney-outcomes-across-the-spectrum-of-kidney-disease-a-systematic-review-and-meta-analysis-mrlirfee 2026-07-15 weekly 0.6 https://asnrt.org/news/early-individualized-recommendations-for-hospitalized-patients-with-acute-kidney-injury-a-randomized-clinical-trial-mqeo495f 2026-06-15 weekly 0.7 https://asnrt.org/ar/news/early-individualized-recommendations-for-hospitalized-patients-with-acute-kidney-injury-a-randomized-clinical-trial-mqeo495f 2026-06-15 weekly 0.6 https://asnrt.org/news/an-international-multi-center-study-evaluated-rituximab-therapy-in-childhood-steroid-resistant-nephrotic-syndrome-mpw2t3hr 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/an-international-multi-center-study-evaluated-rituximab-therapy-in-childhood-steroid-resistant-nephrotic-syndrome-mpw2t3hr 2026-06-08 weekly 0.6 https://asnrt.org/news/finerenone-in-heart-failure-and-chronic-kidney-disease-with-type-2-diabetes-fine-heart-pooled-analysis-of-cardiovascular-kidney-and-mortality-outcomes-mo32pby4 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/finerenone-in-heart-failure-and-chronic-kidney-disease-with-type-2-diabetes-fine-heart-pooled-analysis-of-cardiovascular-kidney-and-mortality-outcomes-mo32pby4 2026-05-31 weekly 0.6 https://asnrt.org/news/clinical-analysis-of-sirolimus-therapy-in-children-with-refractory-nephrotic-syndrome-mqdaz8ag 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/clinical-analysis-of-sirolimus-therapy-in-children-with-refractory-nephrotic-syndrome-mqdaz8ag 2026-06-14 weekly 0.6 https://asnrt.org/news/pathophysiology-of-rejection-in-kidney-transplantation-mqdazmvf 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/pathophysiology-of-rejection-in-kidney-transplantation-mqdazmvf 2026-06-14 weekly 0.6 https://asnrt.org/news/choice-of-dialysis-access-catheter-peritoneal-or-hemodialysis-mr4hz7ns 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/choice-of-dialysis-access-catheter-peritoneal-or-hemodialysis-mr4hz7ns 2026-07-05 weekly 0.6 https://asnrt.org/news/comparison-of-obinutuzumab-and-rituximab-for-treating-primary-membranous-nephropathy-mptbsfb1 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/comparison-of-obinutuzumab-and-rituximab-for-treating-primary-membranous-nephropathy-mptbsfb1 2026-07-05 weekly 0.6 https://asnrt.org/news/semaglutide-in-patients-with-kidney-failure-and-obesity-undergoing-dialysis-and-wishing-to-be-transplanted-mqdiq8dg 2026-06-14 weekly 0.7 https://asnrt.org/ar/news/semaglutide-in-patients-with-kidney-failure-and-obesity-undergoing-dialysis-and-wishing-to-be-transplanted-mqdiq8dg 2026-06-14 weekly 0.6 https://asnrt.org/news/low-dose-spironolactone-and-cardiovascular-outcomes-in-moderate-stage-chronic-kidney-disease-a-randomized-controlled-trial-mrk65thb 2026-07-14 weekly 0.7 https://asnrt.org/ar/news/low-dose-spironolactone-and-cardiovascular-outcomes-in-moderate-stage-chronic-kidney-disease-a-randomized-controlled-trial-mrk65thb 2026-07-14 weekly 0.6 https://asnrt.org/news/the-long-term-effects-of-dapagliflozin-in-chronic-kidney-disease-a-time-to-event-analysis-moi5a5x5 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-long-term-effects-of-dapagliflozin-in-chronic-kidney-disease-a-time-to-event-analysis-moi5a5x5 2026-05-31 weekly 0.6 https://asnrt.org/news/cardiovascular-kidney-and-safety-outcomes-with-glp-1-receptor-agonists-alone-and-in-combination-with-sglt2-inhibitors-in-type-2-diabetes-a-systematic-review-and-meta-analysis-mq3ab8b0 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/cardiovascular-kidney-and-safety-outcomes-with-glp-1-receptor-agonists-alone-and-in-combination-with-sglt2-inhibitors-in-type-2-diabetes-a-systematic-review-and-meta-analysis-mq3ab8b0 2026-06-08 weekly 0.6 https://asnrt.org/news/transition-from-acute-kidney-injury-to-chronic-kidney-disease-mechanisms-models-and-biomarkers-mo859zf7 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/transition-from-acute-kidney-injury-to-chronic-kidney-disease-mechanisms-models-and-biomarkers-mo859zf7 2026-05-28 weekly 0.6 https://asnrt.org/news/finerenone-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction-mptbpbgg 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/finerenone-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction-mptbpbgg 2026-05-31 weekly 0.6 https://asnrt.org/news/management-of-systemic-lupus-erythematosus-a-systematic-literature-review-informing-the-2023-update-of-the-eular-recommendations-moh2c9sr 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/management-of-systemic-lupus-erythematosus-a-systematic-literature-review-informing-the-2023-update-of-the-eular-recommendations-moh2c9sr 2026-05-31 weekly 0.6 https://asnrt.org/news/exploring-platelet-indices-as-predictors-of-nephropathy-severity-in-type-2-diabetes-mellitus-a-hospital-based-cross-sectional-analysis-mphx08pn 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/exploring-platelet-indices-as-predictors-of-nephropathy-severity-in-type-2-diabetes-mellitus-a-hospital-based-cross-sectional-analysis-mphx08pn 2026-05-31 weekly 0.6 https://asnrt.org/news/nice-acute-kidney-injury-guideline-2024-mnu1mn3z 2026-05-27 weekly 0.7 https://asnrt.org/ar/news/nice-acute-kidney-injury-guideline-2024-mnu1mn3z 2026-05-27 weekly 0.6 https://asnrt.org/news/outcome-of-patients-transplanted-for-c3-glomerulopathy-and-primary-immune-complex-mediated-membranoproliferative-glomerulonephritis-mptbzxfk 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/outcome-of-patients-transplanted-for-c3-glomerulopathy-and-primary-immune-complex-mediated-membranoproliferative-glomerulonephritis-mptbzxfk 2026-05-31 weekly 0.6 https://asnrt.org/news/pig-to-human-kidney-xenotransplants-using-genetically-modified-minipigs-mqx8xz5p 2026-06-28 weekly 0.7 https://asnrt.org/ar/news/pig-to-human-kidney-xenotransplants-using-genetically-modified-minipigs-mqx8xz5p 2026-06-28 weekly 0.6 https://asnrt.org/news/vascular-access-for-home-hemodialysis-a-perspective-on-tunneled-central-venous-catheters-at-home-mptc2v6m 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/vascular-access-for-home-hemodialysis-a-perspective-on-tunneled-central-venous-catheters-at-home-mptc2v6m 2026-05-31 weekly 0.6 https://asnrt.org/news/glucagon-like-peptide-1-receptor-agonists-and-kidney-outcomes-mqyn525c 2026-06-29 weekly 0.7 https://asnrt.org/ar/news/glucagon-like-peptide-1-receptor-agonists-and-kidney-outcomes-mqyn525c 2026-06-29 weekly 0.6 https://asnrt.org/news/effects-of-semaglutide-with-and-without-concomitant-sglt2-inhibitor-use-in-type-2-diabetes-and-chronic-kidney-disease-flow-trial-mppcp387 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/effects-of-semaglutide-with-and-without-concomitant-sglt2-inhibitor-use-in-type-2-diabetes-and-chronic-kidney-disease-flow-trial-mppcp387 2026-05-31 weekly 0.6 https://asnrt.org/news/sglt-2-inhibitors-for-adults-with-chronic-kidney-disease-a-clinical-practice-guideline-mppcq6cc 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/sglt-2-inhibitors-for-adults-with-chronic-kidney-disease-a-clinical-practice-guideline-mppcq6cc 2026-05-31 weekly 0.6 https://asnrt.org/news/hyponatraemia-treatment-standard-2024-mpzd12hw 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/hyponatraemia-treatment-standard-2024-mpzd12hw 2026-06-08 weekly 0.6 https://asnrt.org/news/hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-for-anaemia-in-chronic-kidney-disease-a-clinical-practice-document-by-the-european-renal-best-practice-board-of-the-european-renal-association-mpzd968x 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-for-anaemia-in-chronic-kidney-disease-a-clinical-practice-document-by-the-european-renal-best-practice-board-of-the-european-renal-association-mpzd968x 2026-06-08 weekly 0.6 https://asnrt.org/news/novel-insights-into-diabetic-kidney-disease-mqw7ry1f 2026-06-27 weekly 0.7 https://asnrt.org/ar/news/novel-insights-into-diabetic-kidney-disease-mqw7ry1f 2026-06-27 weekly 0.6 https://asnrt.org/news/biomarkers-in-acute-kidney-injury-mpw2ve67 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/biomarkers-in-acute-kidney-injury-mpw2ve67 2026-06-08 weekly 0.6 https://asnrt.org/news/combination-therapy-with-rituximab-and-low-dose-cyclophosphamide-and-prednisone-in-membranous-nephropathy-mr78rey1 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/combination-therapy-with-rituximab-and-low-dose-cyclophosphamide-and-prednisone-in-membranous-nephropathy-mr78rey1 2026-07-05 weekly 0.6 https://asnrt.org/news/the-time-has-come-the-case-for-initiating-pilot-clinical-trials-of-pig-kidney-xenotransplantation-mqx8xku7 2026-06-28 weekly 0.7 https://asnrt.org/ar/news/the-time-has-come-the-case-for-initiating-pilot-clinical-trials-of-pig-kidney-xenotransplantation-mqx8xku7 2026-06-28 weekly 0.6 https://asnrt.org/news/clinical-practice-guideline-for-the-prevention-and-management-of-peritoneal-dialysis-associated-infections-in-children-2024-update-mphwyvbd 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/clinical-practice-guideline-for-the-prevention-and-management-of-peritoneal-dialysis-associated-infections-in-children-2024-update-mphwyvbd 2026-05-31 weekly 0.6 https://asnrt.org/news/plant-based-diet-in-hyperkalemic-chronic-kidney-disease-patients-receiving-sodium-zirconium-cyclosilicate-a-feasibility-clinical-trial-mpw2qv9k 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/plant-based-diet-in-hyperkalemic-chronic-kidney-disease-patients-receiving-sodium-zirconium-cyclosilicate-a-feasibility-clinical-trial-mpw2qv9k 2026-06-08 weekly 0.6 https://asnrt.org/news/peritoneal-dialysis-technique-survival-a-cohort-study-mq62rtcb 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/peritoneal-dialysis-technique-survival-a-cohort-study-mq62rtcb 2026-06-09 weekly 0.6 https://asnrt.org/news/the-second-international-consensus-guidelines-on-the-management-of-bk-polyomavirus-in-kidney-transplantation-moqmoti2 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-second-international-consensus-guidelines-on-the-management-of-bk-polyomavirus-in-kidney-transplantation-moqmoti2 2026-05-31 weekly 0.6 https://asnrt.org/news/a-randomized-trial-of-intravenous-amino-acids-for-kidney-protection-mq2feiow 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/a-randomized-trial-of-intravenous-amino-acids-for-kidney-protection-mq2feiow 2026-06-08 weekly 0.6 https://asnrt.org/news/chronic-kidney-disease-detect-diagnose-disclose-a-uk-primary-care-perspective-of-barriers-and-enablers-to-effective-kidney-care-mo32r7mp 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/chronic-kidney-disease-detect-diagnose-disclose-a-uk-primary-care-perspective-of-barriers-and-enablers-to-effective-kidney-care-mo32r7mp 2026-05-31 weekly 0.6 https://asnrt.org/news/cellular-dynamics-in-pig-to-human-kidney-xenotransplantation-moh2koi2 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/cellular-dynamics-in-pig-to-human-kidney-xenotransplantation-moh2koi2 2026-05-28 weekly 0.6 https://asnrt.org/news/vascular-access-considerations-in-home-hemodialysis-mruj0i0u 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/vascular-access-considerations-in-home-hemodialysis-mruj0i0u 2026-07-21 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8ln4 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8ln4 2026-07-21 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8ln8 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8ln8 2026-07-21 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8lm7 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8lm7 2026-07-21 weekly 0.6 https://asnrt.org/news/sodium-bicarbonate-treatment-and-clinical-outcomes-in-chronic-kidney-disease-with-metabolic-acidosis-a-meta-analysis-mr78jxss 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/sodium-bicarbonate-treatment-and-clinical-outcomes-in-chronic-kidney-disease-with-metabolic-acidosis-a-meta-analysis-mr78jxss 2026-07-05 weekly 0.6 https://asnrt.org/news/new-therapies-for-highly-sensitized-patients-on-the-waiting-list-mpldu2bw 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/new-therapies-for-highly-sensitized-patients-on-the-waiting-list-mpldu2bw 2026-05-31 weekly 0.6 https://asnrt.org/news/balcinrenone-plus-dapagliflozin-in-patients-with-heart-failure-and-chronic-kidney-disease-results-from-the-phase-2b-miracle-trial-moo2eqip 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/balcinrenone-plus-dapagliflozin-in-patients-with-heart-failure-and-chronic-kidney-disease-results-from-the-phase-2b-miracle-trial-moo2eqip 2026-05-31 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8lna 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1-receptor-agonists-a-smart-c-collaborative-meta-analysis-of-randomised-controlled-trials-mruj8lna 2026-07-21 weekly 0.6 https://asnrt.org/news/imlifidase-in-highly-sensitized-kidney-transplant-recipients-with-a-positive-crossmatch-against-a-deceased-donor-mptby6pm 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/imlifidase-in-highly-sensitized-kidney-transplant-recipients-with-a-positive-crossmatch-against-a-deceased-donor-mptby6pm 2026-05-31 weekly 0.6 https://asnrt.org/news/advances-in-primary-glomerulonephritis-mppcyi1c 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/advances-in-primary-glomerulonephritis-mppcyi1c 2026-05-31 weekly 0.6 https://asnrt.org/news/a-randomized-phase-2-trial-of-felzartamab-in-antibody-mediated-rejection-mpw2zp7r 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/a-randomized-phase-2-trial-of-felzartamab-in-antibody-mediated-rejection-mpw2zp7r 2026-06-08 weekly 0.6 https://asnrt.org/news/semaglutide-and-kidney-outcomes-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-mnqwsiyr 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/semaglutide-and-kidney-outcomes-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-mnqwsiyr 2026-05-31 weekly 0.6 https://asnrt.org/news/effects-of-semaglutide-on-chronic-kidney-disease-in-patients-with-type-2-diabetes-moh2lqgx 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/effects-of-semaglutide-on-chronic-kidney-disease-in-patients-with-type-2-diabetes-moh2lqgx 2026-05-31 weekly 0.6 https://asnrt.org/news/frailty-in-patients-on-dialysis-mqx8w4mg 2026-06-28 weekly 0.7 https://asnrt.org/ar/news/frailty-in-patients-on-dialysis-mqx8w4mg 2026-06-28 weekly 0.6 https://asnrt.org/news/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease-in-the-select-trial-mpw2xsv9 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease-in-the-select-trial-mpw2xsv9 2026-06-08 weekly 0.6 https://asnrt.org/news/xenotransplantation-clinical-trials-and-equitable-patient-selection-mqx8wn0l 2026-06-28 weekly 0.7 https://asnrt.org/ar/news/xenotransplantation-clinical-trials-and-equitable-patient-selection-mqx8wn0l 2026-06-28 weekly 0.6 https://asnrt.org/news/acute-kidney-injury-in-patients-with-cirrhosis-acute-disease-quality-initiative-adqi-and-international-club-of-ascites-ica-joint-multidisciplinary-consensus-meeting-moh2bszz 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/acute-kidney-injury-in-patients-with-cirrhosis-acute-disease-quality-initiative-adqi-and-international-club-of-ascites-ica-joint-multidisciplinary-consensus-meeting-moh2bszz 2026-05-31 weekly 0.6 https://asnrt.org/news/real-world-effectiveness-of-preventive-pharmacological-therapy-in-patients-with-urolithiasis-a-retrospective-cohort-study-mpw2uibe 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/real-world-effectiveness-of-preventive-pharmacological-therapy-in-patients-with-urolithiasis-a-retrospective-cohort-study-mpw2uibe 2026-06-08 weekly 0.6 https://asnrt.org/news/phase-1b2a-study-assessing-the-safety-and-efficacy-of-felzartamab-in-anti-phospholipase-a2-receptor-autoantibody-positive-primary-membranous-nephropathy-mptbrkt7 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/phase-1b2a-study-assessing-the-safety-and-efficacy-of-felzartamab-in-anti-phospholipase-a2-receptor-autoantibody-positive-primary-membranous-nephropathy-mptbrkt7 2026-05-31 weekly 0.6 https://asnrt.org/news/characterizing-patients-presenting-on-hospital-admission-with-central-line-associated-bloodstream-infections-a-multicenter-study-mr78go5k 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/characterizing-patients-presenting-on-hospital-admission-with-central-line-associated-bloodstream-infections-a-multicenter-study-mr78go5k 2026-07-05 weekly 0.6 https://asnrt.org/news/sodium-glucose-cotransporter-2-inhibitors-and-major-adverse-cardiovascular-outcomes-a-smart-c-collaborative-meta-analysis-mpzcsi4d 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sodium-glucose-cotransporter-2-inhibitors-and-major-adverse-cardiovascular-outcomes-a-smart-c-collaborative-meta-analysis-mpzcsi4d 2026-06-08 weekly 0.6 https://asnrt.org/news/a-review-of-the-current-recommendations-and-practices-for-hemodialysis-access-monitoring-and-maintenance-procedures-mozei2oe 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/a-review-of-the-current-recommendations-and-practices-for-hemodialysis-access-monitoring-and-maintenance-procedures-mozei2oe 2026-05-28 weekly 0.6 https://asnrt.org/news/recurrence-of-membranous-nephropathy-after-kidney-transplantation-a-multicenter-retrospective-cohort-study-mr78s4c0 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/recurrence-of-membranous-nephropathy-after-kidney-transplantation-a-multicenter-retrospective-cohort-study-mr78s4c0 2026-07-05 weekly 0.6 https://asnrt.org/news/anca-associated-vasculitis-treatment-standard-mpzd49ss 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/anca-associated-vasculitis-treatment-standard-mpzd49ss 2026-06-08 weekly 0.6 https://asnrt.org/news/clinical-islet-xenotransplantation-development-of-isolation-protocol-anti-rejection-strategies-and-clinical-outcomes-mp9h9olr 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/clinical-islet-xenotransplantation-development-of-isolation-protocol-anti-rejection-strategies-and-clinical-outcomes-mp9h9olr 2026-05-31 weekly 0.6 https://asnrt.org/news/a-prospective-randomized-controlled-clinical-study-to-investigate-the-efficacy-and-safety-of-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-in-non-dialysis-patients-with-chronic-heart-failure--mru45z3t 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/a-prospective-randomized-controlled-clinical-study-to-investigate-the-efficacy-and-safety-of-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-in-non-dialysis-patients-with-chronic-heart-failure--mru45z3t 2026-07-21 weekly 0.6 https://asnrt.org/news/a-prospective-randomized-controlled-clinical-study-to-investigate-the-efficacy-and-safety-of-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-in-non-dialysis-patients-with-chronic-heart-failure--mru45z3v 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/a-prospective-randomized-controlled-clinical-study-to-investigate-the-efficacy-and-safety-of-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-in-non-dialysis-patients-with-chronic-heart-failure--mru45z3v 2026-07-21 weekly 0.6 https://asnrt.org/news/predictive-value-of-the-domain-specific-pla2r-antibodies-for-clinical-remission-in-patients-with-primary-membranous-nephropathy-mr78pj11 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/predictive-value-of-the-domain-specific-pla2r-antibodies-for-clinical-remission-in-patients-with-primary-membranous-nephropathy-mr78pj11 2026-07-05 weekly 0.6 https://asnrt.org/news/systemic-lupus-erythematosus-a-review-mr4hzzqh 2026-07-03 weekly 0.7 https://asnrt.org/ar/news/systemic-lupus-erythematosus-a-review-mr4hzzqh 2026-07-03 weekly 0.6 https://asnrt.org/news/peritoneal-dialysis-in-the-arabian-gulf-countries-challenges-and-opportunities-mo32qe2g 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/peritoneal-dialysis-in-the-arabian-gulf-countries-challenges-and-opportunities-mo32qe2g 2026-05-31 weekly 0.6 https://asnrt.org/news/long-term-outcomes-after-conversion-to-a-belatacept-based-immunosuppression-in-kidney-transplant-recipients-mnsue42o 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/long-term-outcomes-after-conversion-to-a-belatacept-based-immunosuppression-in-kidney-transplant-recipients-mnsue42o 2026-05-31 weekly 0.6 https://asnrt.org/news/academy-of-nutrition-and-dietetics-commentary-on-the-phosphorus-recommendation-in-the-kdoqi-clinical-practice-guidelines-for-nutrition-in-ckd-2020-update-moo2fffu 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/academy-of-nutrition-and-dietetics-commentary-on-the-phosphorus-recommendation-in-the-kdoqi-clinical-practice-guidelines-for-nutrition-in-ckd-2020-update-moo2fffu 2026-05-31 weekly 0.6 https://asnrt.org/news/long-term-outcomes-after-conversion-to-a-belatacept-based-immunosuppression-in-kidney-transplant-recipients-mruj34ic 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/long-term-outcomes-after-conversion-to-a-belatacept-based-immunosuppression-in-kidney-transplant-recipients-mruj34ic 2026-07-21 weekly 0.6 https://asnrt.org/news/sglt2-inhibitors-from-glucose-lowering-to-cardiovascular-benefits-mqq5uqi6 2026-06-23 weekly 0.7 https://asnrt.org/ar/news/sglt2-inhibitors-from-glucose-lowering-to-cardiovascular-benefits-mqq5uqi6 2026-06-23 weekly 0.6 https://asnrt.org/news/arteriovenous-access-for-hemodialysis-a-review-mq2dhuh5 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/arteriovenous-access-for-hemodialysis-a-review-mq2dhuh5 2026-06-08 weekly 0.6 https://asnrt.org/news/efficacy-of-combined-rituximab-and-daratumumab-treatment-in-posttransplant-recurrent-focal-segmental-glomerulosclerosis-mq2diwto 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/efficacy-of-combined-rituximab-and-daratumumab-treatment-in-posttransplant-recurrent-focal-segmental-glomerulosclerosis-mq2diwto 2026-06-08 weekly 0.6 https://asnrt.org/news/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-known-knowns-and-known-unknowns-mojig72n 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-known-knowns-and-known-unknowns-mojig72n 2026-05-31 weekly 0.6 https://asnrt.org/news/hepatorenal-syndrome-in-cirrhosis-mr4hyvpi 2026-07-03 weekly 0.7 https://asnrt.org/ar/news/hepatorenal-syndrome-in-cirrhosis-mr4hyvpi 2026-07-03 weekly 0.6 https://asnrt.org/news/kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-moh28nz3 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-moh28nz3 2026-05-31 weekly 0.6 https://asnrt.org/news/benralizumab-versus-mepolizumab-for-eosinophilic-granulomatosis-with-polyangiitis-mqq5uesm 2026-06-23 weekly 0.7 https://asnrt.org/ar/news/benralizumab-versus-mepolizumab-for-eosinophilic-granulomatosis-with-polyangiitis-mqq5uesm 2026-06-23 weekly 0.6 https://asnrt.org/news/global-variability-of-vascular-and-peritoneal-access-for-chronic-dialysis-moo2gy83 2026-05-27 weekly 0.7 https://asnrt.org/ar/news/global-variability-of-vascular-and-peritoneal-access-for-chronic-dialysis-moo2gy83 2026-05-27 weekly 0.6 https://asnrt.org/news/isatuximab-monotherapy-for-desensitization-in-highly-sensitized-patients-awaiting-kidney-transplant-mppc4jsv 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/isatuximab-monotherapy-for-desensitization-in-highly-sensitized-patients-awaiting-kidney-transplant-mppc4jsv 2026-05-31 weekly 0.6 https://asnrt.org/news/the-banff-2022-kidney-meeting-work-plan-data-driven-refinement-of-the-banff-classification-for-renal-allografts-moh26liy 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-banff-2022-kidney-meeting-work-plan-data-driven-refinement-of-the-banff-classification-for-renal-allografts-moh26liy 2026-05-31 weekly 0.6 https://asnrt.org/news/the-banff-2022-kidney-meeting-report-reappraisal-of-microvascular-inflammation-and-the-role-of-biopsy-based-transcript-diagnostics-mo32tg20 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-banff-2022-kidney-meeting-report-reappraisal-of-microvascular-inflammation-and-the-role-of-biopsy-based-transcript-diagnostics-mo32tg20 2026-05-31 weekly 0.6 https://asnrt.org/news/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-management-of-anca-associated-vasculitis-mppco6zt 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-management-of-anca-associated-vasculitis-mppco6zt 2026-05-31 weekly 0.6 https://asnrt.org/news/combined-islet-and-kidney-xenotransplantation-for-diabetic-nephropathy-an-update-in-ongoing-research-for-a-clinically-relevant-application-of-porcine-islet-transplantation-mqeo30od 2026-06-15 weekly 0.7 https://asnrt.org/ar/news/combined-islet-and-kidney-xenotransplantation-for-diabetic-nephropathy-an-update-in-ongoing-research-for-a-clinically-relevant-application-of-porcine-islet-transplantation-mqeo30od 2026-06-15 weekly 0.6 https://asnrt.org/news/advances-in-organ-and-tissue-xenotransplantation-mobi6j2q 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/advances-in-organ-and-tissue-xenotransplantation-mobi6j2q 2026-05-31 weekly 0.6 https://asnrt.org/news/estimated-lifetime-cardiovascular-kidney-and-mortality-benefits-of-combination-treatment-with-sglt2-inhibitors-glp-1-receptor-agonists-and-nonsteroidal-mra-compared-with-conventional-care-in-patients--mo32l55q 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/estimated-lifetime-cardiovascular-kidney-and-mortality-benefits-of-combination-treatment-with-sglt2-inhibitors-glp-1-receptor-agonists-and-nonsteroidal-mra-compared-with-conventional-care-in-patients--mo32l55q 2026-05-31 weekly 0.6 https://asnrt.org/news/estimated-lifetime-cardiovascular-kidney-and-mortality-benefits-of-combination-treatment-with-sglt2-inhibitors-glp-1-receptor-agonists-and-nonsteroidal-mra-compared-with-conventional-care-in-patients--mruj98ef 2026-07-21 weekly 0.7 https://asnrt.org/ar/news/estimated-lifetime-cardiovascular-kidney-and-mortality-benefits-of-combination-treatment-with-sglt2-inhibitors-glp-1-receptor-agonists-and-nonsteroidal-mra-compared-with-conventional-care-in-patients--mruj98ef 2026-07-21 weekly 0.6 https://asnrt.org/news/development-and-validation-of-the-american-heart-associations-prevent-equations-mppcy49a 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/development-and-validation-of-the-american-heart-associations-prevent-equations-mppcy49a 2026-05-31 weekly 0.6 https://asnrt.org/news/comparison-of-2-immunosuppression-minimization-strategies-in-kidney-transplantation-the-allegro-trial-mq2fge3g 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/comparison-of-2-immunosuppression-minimization-strategies-in-kidney-transplantation-the-allegro-trial-mq2fge3g 2026-06-08 weekly 0.6 https://asnrt.org/news/kidney-outcomes-and-preservation-of-kidney-function-with-obinutuzumab-in-patients-with-lupus-nephritis-a-post-hoc-analysis-of-the-nobility-trial-mr4hzm5n 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/kidney-outcomes-and-preservation-of-kidney-function-with-obinutuzumab-in-patients-with-lupus-nephritis-a-post-hoc-analysis-of-the-nobility-trial-mr4hzm5n 2026-07-05 weekly 0.6 https://asnrt.org/news/therapeutic-apheresis-in-renal-transplantation-an-update-mp2u2unw 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/therapeutic-apheresis-in-renal-transplantation-an-update-mp2u2unw 2026-05-31 weekly 0.6 https://asnrt.org/news/non-immunosuppressive-treatment-for-iga-nephropathy-moh2ac7q 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/non-immunosuppressive-treatment-for-iga-nephropathy-moh2ac7q 2026-05-31 weekly 0.6 https://asnrt.org/news/cardiovascular-outcomes-in-patients-on-home-hemodialysis-and-peritoneal-dialysis-mo857dd2 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/cardiovascular-outcomes-in-patients-on-home-hemodialysis-and-peritoneal-dialysis-mo857dd2 2026-05-31 weekly 0.6 https://asnrt.org/news/effect-of-dialysate-and-plasma-sodium-on-mortality-in-a-global-historical-hemodialysis-cohort-mp1g4s24 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/effect-of-dialysate-and-plasma-sodium-on-mortality-in-a-global-historical-hemodialysis-cohort-mp1g4s24 2026-05-31 weekly 0.6 https://asnrt.org/news/the-peritoneal-membrane-and-its-role-in-peritoneal-dialysis-mo32sqob 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-peritoneal-membrane-and-its-role-in-peritoneal-dialysis-mo32sqob 2026-05-31 weekly 0.6 https://asnrt.org/news/effect-of-intensive-blood-pressure-control-on-kidney-outcomes-long-term-electronic-health-record-based-post-trial-follow-up-of-sprint-mp55vhr9 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/effect-of-intensive-blood-pressure-control-on-kidney-outcomes-long-term-electronic-health-record-based-post-trial-follow-up-of-sprint-mp55vhr9 2026-05-31 weekly 0.6 https://asnrt.org/news/focal-segmental-glomerulosclerosis-patient-baseline-characteristics-in-the-sparsentan-phase-3-duplex-study-mo856gmw 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/focal-segmental-glomerulosclerosis-patient-baseline-characteristics-in-the-sparsentan-phase-3-duplex-study-mo856gmw 2026-05-31 weekly 0.6 https://asnrt.org/news/implementation-of-chronic-kidney-disease-guidelines-for-sodium-glucose-co-transporter-2-inhibitor-use-in-primary-care-in-the-uk-a-cross-sectional-study-mp1g5vp3 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/implementation-of-chronic-kidney-disease-guidelines-for-sodium-glucose-co-transporter-2-inhibitor-use-in-primary-care-in-the-uk-a-cross-sectional-study-mp1g5vp3 2026-05-31 weekly 0.6 https://asnrt.org/news/developments-in-kidney-xenotransplantation-mpfclgb0 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/developments-in-kidney-xenotransplantation-mpfclgb0 2026-05-31 weekly 0.6 https://asnrt.org/news/alkaline-phosphatase-and-parathyroid-hormone-levels-international-variation-and-associations-with-clinical-outcomes-in-the-dopps-mq62qzls 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/alkaline-phosphatase-and-parathyroid-hormone-levels-international-variation-and-associations-with-clinical-outcomes-in-the-dopps-mq62qzls 2026-06-09 weekly 0.6 https://asnrt.org/news/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-2023-update-moi58flf 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-2023-update-moi58flf 2026-05-31 weekly 0.6 https://asnrt.org/news/efficacy-of-finerenone-in-patients-with-type-2-diabetes-chronic-kidney-disease-and-altered-markers-of-liver-steatosis-and-fibrosis-a-fidelity-subgroup-analysis-mpzctd9j 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/efficacy-of-finerenone-in-patients-with-type-2-diabetes-chronic-kidney-disease-and-altered-markers-of-liver-steatosis-and-fibrosis-a-fidelity-subgroup-analysis-mpzctd9j 2026-06-08 weekly 0.6 https://asnrt.org/news/iscn-2024---an-international-system-for-human-cytogenomic-nomenclature-2024-mo32oils 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/iscn-2024---an-international-system-for-human-cytogenomic-nomenclature-2024-mo32oils 2026-05-31 weekly 0.6 https://asnrt.org/news/results-of-a-randomized-double-blind-placebo-controlled-phase-2-study-propose-iptacopan-as-an-alternative-complement-pathway-inhibitor-for-iga-nephropathy-mppcvra6 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/results-of-a-randomized-double-blind-placebo-controlled-phase-2-study-propose-iptacopan-as-an-alternative-complement-pathway-inhibitor-for-iga-nephropathy-mppcvra6 2026-05-31 weekly 0.6 https://asnrt.org/news/xenotransplantation-literature-update-march-2023-november-2023-mp55uhou 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/xenotransplantation-literature-update-march-2023-november-2023-mp55uhou 2026-05-31 weekly 0.6 https://asnrt.org/news/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified-secondary-analysis-from-the-empa-kidney-trial-mppcrgtf 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified-secondary-analysis-from-the-empa-kidney-trial-mppcrgtf 2026-05-31 weekly 0.6 https://asnrt.org/news/treatment-of-iga-nephropathy-a-rapidly-evolving-field-mnsudgby 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/treatment-of-iga-nephropathy-a-rapidly-evolving-field-mnsudgby 2026-05-31 weekly 0.6 https://asnrt.org/news/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-management-of-lupus-nephritis-moh275tn 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-management-of-lupus-nephritis-moh275tn 2026-05-31 weekly 0.6 https://asnrt.org/news/the-efficacy-and-safety-of-sacubitrilvalsartan-in-chronic-kidney-disease-a-systematic-review-and-meta-analysis-mp1g69ny 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-efficacy-and-safety-of-sacubitrilvalsartan-in-chronic-kidney-disease-a-systematic-review-and-meta-analysis-mp1g69ny 2026-05-31 weekly 0.6 https://asnrt.org/news/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis-duplex-mq62m455 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis-duplex-mq62m455 2026-07-05 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-sparsentan-in-patients-with-fsgs-results-from-the-pivotal-phase-3-duplex-3-study-mnst3xo2 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-sparsentan-in-patients-with-fsgs-results-from-the-pivotal-phase-3-duplex-3-study-mnst3xo2 2026-05-31 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga-nephropathy-protect-2-year-results-from-a-randomised-active-controlled-phase-3-trial-moh2hy5w 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga-nephropathy-protect-2-year-results-from-a-randomised-active-controlled-phase-3-trial-moh2hy5w 2026-05-31 weekly 0.6 https://asnrt.org/news/updated-evidence-of-beneficial-effect-of-ldl-apheresis-for-refractory-nephrotic-syndrome-due-to-a-variety-of-causative-diseases-for-nationwide-and-global-approval-mp2u1xpp 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/updated-evidence-of-beneficial-effect-of-ldl-apheresis-for-refractory-nephrotic-syndrome-due-to-a-variety-of-causative-diseases-for-nationwide-and-global-approval-mp2u1xpp 2026-05-31 weekly 0.6 https://asnrt.org/news/impact-of-finerenone-induced-albuminuria-reduction-on-chronic-kidney-disease-outcomes-in-type-2-diabetes-a-mediation-analysis-moh29ai6 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/impact-of-finerenone-induced-albuminuria-reduction-on-chronic-kidney-disease-outcomes-in-type-2-diabetes-a-mediation-analysis-moh29ai6 2026-05-31 weekly 0.6 https://asnrt.org/news/daratumumab-for-antibody-mediated-rejection-is-it-time-to-target-the-real-culprit-mq62k4j6 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/daratumumab-for-antibody-mediated-rejection-is-it-time-to-target-the-real-culprit-mq62k4j6 2026-06-09 weekly 0.6 https://asnrt.org/news/real-world-usage-of-chronic-kidney-disease---mineral-bone-disorder-ckd-mbd-biomarkers-in-nephrology-practices-moi59jnc 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/real-world-usage-of-chronic-kidney-disease---mineral-bone-disorder-ckd-mbd-biomarkers-in-nephrology-practices-moi59jnc 2026-05-31 weekly 0.6 https://asnrt.org/news/consensus-document-on-the-management-of-hyperkalemia-mqj7qen0 2026-06-18 weekly 0.7 https://asnrt.org/ar/news/consensus-document-on-the-management-of-hyperkalemia-mqj7qen0 2026-06-18 weekly 0.6 https://asnrt.org/news/nutrition-in-peritoneal-dialysis-moi57enf 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/nutrition-in-peritoneal-dialysis-moi57enf 2026-05-28 weekly 0.6 https://asnrt.org/news/vitamin-d-therapy-in-adults-with-ckd-a-systematic-review-and-meta-analysis-mq62qgfb 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/vitamin-d-therapy-in-adults-with-ckd-a-systematic-review-and-meta-analysis-mq62qgfb 2026-06-09 weekly 0.6 https://asnrt.org/news/association-between-ckd-mbd-and-mortality-in-older-patients-with-advanced-ckd-results-from-the-equal-study-mq62put5 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/association-between-ckd-mbd-and-mortality-in-older-patients-with-advanced-ckd-results-from-the-equal-study-mq62put5 2026-06-09 weekly 0.6 https://asnrt.org/news/renal-function-and-decongestion-with-acetazolamide-in-acute-decompensated-heart-failure-the-advor-trial-mpzcx8gx 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/renal-function-and-decongestion-with-acetazolamide-in-acute-decompensated-heart-failure-the-advor-trial-mpzcx8gx 2026-06-08 weekly 0.6 https://asnrt.org/news/immune-response-after-pig-to-human-kidney-xenotransplantation-a-multimodal-phenotyping-study-mozj0exq 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/immune-response-after-pig-to-human-kidney-xenotransplantation-a-multimodal-phenotyping-study-mozj0exq 2026-05-31 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-a-targeted-release-formulation-of-budesonide-in-patients-with-primary-iga-nephropathy-nefigard-2-year-results-from-a-randomised-phase-3-trial-mppcw80r 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-a-targeted-release-formulation-of-budesonide-in-patients-with-primary-iga-nephropathy-nefigard-2-year-results-from-a-randomised-phase-3-trial-mppcw80r 2026-05-31 weekly 0.6 https://asnrt.org/news/childhood-nephrotic-syndrome-mpw2tl02 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/childhood-nephrotic-syndrome-mpw2tl02 2026-06-08 weekly 0.6 https://asnrt.org/news/evaluation-of-the-modified-oxford-score-in-recurrent-iga-nephropathy-in-north-american-kidney-transplant-recipients-the-banff-recurrent-glomerulonephritis-working-group-report-mptc0hai 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/evaluation-of-the-modified-oxford-score-in-recurrent-iga-nephropathy-in-north-american-kidney-transplant-recipients-the-banff-recurrent-glomerulonephritis-working-group-report-mptc0hai 2026-05-31 weekly 0.6 https://asnrt.org/news/diagnosis-prevention-and-treatment-of-infections-in-kidney-transplantation-moh2n1r1 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/diagnosis-prevention-and-treatment-of-infections-in-kidney-transplantation-moh2n1r1 2026-05-28 weekly 0.6 https://asnrt.org/news/the-rationale-design-and-baseline-data-of-flow-a-kidney-outcomes-trial-with-once-weekly-semaglutide-in-people-with-type-2-diabetes-and-chronic-kidney-disease-mp9h7iu5 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-rationale-design-and-baseline-data-of-flow-a-kidney-outcomes-trial-with-once-weekly-semaglutide-in-people-with-type-2-diabetes-and-chronic-kidney-disease-mp9h7iu5 2026-05-31 weekly 0.6 https://asnrt.org/news/crispr-cas9-editing-of-the-hbg1-and-hbg2-promoters-to-treat-sickle-cell-disease-mp9h4xvu 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/crispr-cas9-editing-of-the-hbg1-and-hbg2-promoters-to-treat-sickle-cell-disease-mp9h4xvu 2026-05-31 weekly 0.6 https://asnrt.org/news/comparative-efficacy-and-safety-of-immunosuppressive-strategies-in-kidney-transplantation-a-network-meta-analysis-mnrbi0t6 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/comparative-efficacy-and-safety-of-immunosuppressive-strategies-in-kidney-transplantation-a-network-meta-analysis-mnrbi0t6 2026-05-31 weekly 0.6 https://asnrt.org/news/implications-of-complete-proteinuria-remission-at-any-time-in-focal-segmental-glomerulosclerosis-sparsentan-duet-trial-mp56tnvw 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/implications-of-complete-proteinuria-remission-at-any-time-in-focal-segmental-glomerulosclerosis-sparsentan-duet-trial-mp56tnvw 2026-05-31 weekly 0.6 https://asnrt.org/news/cardiac-and-kidney-benefits-of-empagliflozin-in-heart-failure-across-the-spectrum-of-kidney-function-insights-from-the-emperor-preserved-trial-mppc0ygu 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/cardiac-and-kidney-benefits-of-empagliflozin-in-heart-failure-across-the-spectrum-of-kidney-function-insights-from-the-emperor-preserved-trial-mppc0ygu 2026-07-05 weekly 0.6 https://asnrt.org/news/kdoqi-us-commentary-on-the-2021-kdigo-clinical-practice-guideline-for-the-management-of-glomerular-diseases-mozenk64 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/kdoqi-us-commentary-on-the-2021-kdigo-clinical-practice-guideline-for-the-management-of-glomerular-diseases-mozenk64 2026-05-31 weekly 0.6 https://asnrt.org/news/graft-dysfunction-in-compassionate-use-of-genetically-engineered-pig-to-human-cardiac-xenotransplantation-a-case-report-mp55v1gs 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/graft-dysfunction-in-compassionate-use-of-genetically-engineered-pig-to-human-cardiac-xenotransplantation-a-case-report-mp55v1gs 2026-05-31 weekly 0.6 https://asnrt.org/news/effects-of-oral-semaglutide-on-cardiovascular-outcomes-in-individuals-with-type-2-diabetes-and-established-atherosclerotic-cardiovascular-disease-andor-chronic-kidney-disease-design-and-baseline-chara-mos2cr3g 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/effects-of-oral-semaglutide-on-cardiovascular-outcomes-in-individuals-with-type-2-diabetes-and-established-atherosclerotic-cardiovascular-disease-andor-chronic-kidney-disease-design-and-baseline-chara-mos2cr3g 2026-05-31 weekly 0.6 https://asnrt.org/news/the-long-acting-c5-inhibitor-ravulizumab-is-effective-and-safe-in-pediatric-patients-with-atypical-hemolytic-uremic-syndrome-nave-to-complement-inhibitor-treatment-mptbwt4k 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/the-long-acting-c5-inhibitor-ravulizumab-is-effective-and-safe-in-pediatric-patients-with-atypical-hemolytic-uremic-syndrome-nave-to-complement-inhibitor-treatment-mptbwt4k 2026-05-31 weekly 0.6 https://asnrt.org/news/current-status-regarding-immunosuppressive-treatment-in-patients-after-renal-transplantation-moi58yrc 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/current-status-regarding-immunosuppressive-treatment-in-patients-after-renal-transplantation-moi58yrc 2026-05-31 weekly 0.6 https://asnrt.org/news/steroid-sparing-maintenance-immunosuppression-in-highly-sensitised-patients-receiving-alemtuzumab-induction-mozj4c5l 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/steroid-sparing-maintenance-immunosuppression-in-highly-sensitised-patients-receiving-alemtuzumab-induction-mozj4c5l 2026-05-31 weekly 0.6 https://asnrt.org/news/sepsis-associated-acute-kidney-injury-consensus-report-of-the-28th-acute-disease-quality-initiative-workgroup-mpw2w3ml 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sepsis-associated-acute-kidney-injury-consensus-report-of-the-28th-acute-disease-quality-initiative-workgroup-mpw2w3ml 2026-06-08 weekly 0.6 https://asnrt.org/news/long-term-outcomes-in-iga-nephropathy-mojif263 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/long-term-outcomes-in-iga-nephropathy-mojif263 2026-05-31 weekly 0.6 https://asnrt.org/news/glucagon-like-peptide-1-receptor-agonists-in-diabetic-kidney-disease-a-review-of-their-kidney-and-heart-protection-mp9h5qvr 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/glucagon-like-peptide-1-receptor-agonists-in-diabetic-kidney-disease-a-review-of-their-kidney-and-heart-protection-mp9h5qvr 2026-05-31 weekly 0.6 https://asnrt.org/news/home-dialysis-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference-moh2dw43 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/home-dialysis-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference-moh2dw43 2026-05-31 weekly 0.6 https://asnrt.org/news/update-on-diabetic-kidney-disease-dkd-focus-on-non-albuminuric-dkd-and-cardiovascular-risk-mp9h8mh3 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/update-on-diabetic-kidney-disease-dkd-focus-on-non-albuminuric-dkd-and-cardiovascular-risk-mp9h8mh3 2026-05-31 weekly 0.6 https://asnrt.org/news/design-of-the-combination-effect-of-finerenone-and-empagliflozin-in-participants-with-chronic-kidney-disease-and-type-2-diabetes-using-a-uacr-endpoint-study-confidence-mozj0rl2 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/design-of-the-combination-effect-of-finerenone-and-empagliflozin-in-participants-with-chronic-kidney-disease-and-type-2-diabetes-using-a-uacr-endpoint-study-confidence-mozj0rl2 2026-05-31 weekly 0.6 https://asnrt.org/news/inaxaplin-for-proteinuric-kidney-disease-in-persons-with-two-apol1-variants-mppcx3mq 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/inaxaplin-for-proteinuric-kidney-disease-in-persons-with-two-apol1-variants-mppcx3mq 2026-05-31 weekly 0.6 https://asnrt.org/news/hydrochlorothiazide-and-prevention-of-kidney-stone-recurrence-mpw2x1kh 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/hydrochlorothiazide-and-prevention-of-kidney-stone-recurrence-mpw2x1kh 2026-07-05 weekly 0.6 https://asnrt.org/news/kdigo-diabetes-chronic-kidney-disease-guideline-2023-update-moh2j2qb 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/kdigo-diabetes-chronic-kidney-disease-guideline-2023-update-moh2j2qb 2026-05-28 weekly 0.6 https://asnrt.org/news/attitudes-of-patients-with-renal-disease-on-xenotransplantation-a-systematic-review-mppczok2 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/attitudes-of-patients-with-renal-disease-on-xenotransplantation-a-systematic-review-mppczok2 2026-05-31 weekly 0.6 https://asnrt.org/news/use-of-belatacept-in-kidney-transplantation-whats-new-mra3go23 2026-07-07 weekly 0.7 https://asnrt.org/ar/news/use-of-belatacept-in-kidney-transplantation-whats-new-mra3go23 2026-07-07 weekly 0.6 https://asnrt.org/news/recurrence-of-immune-complex-and-complement-mediated-membranoproliferative-glomerulonephritis-in-kidney-transplantation-mptc17kc 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/recurrence-of-immune-complex-and-complement-mediated-membranoproliferative-glomerulonephritis-in-kidney-transplantation-mptc17kc 2026-05-31 weekly 0.6 https://asnrt.org/news/chronic-kidney-disease-and-obesity-mp55ts0l 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/chronic-kidney-disease-and-obesity-mp55ts0l 2026-05-31 weekly 0.6 https://asnrt.org/news/barriers-to-home-haemodialysis-mp9h6b08 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/barriers-to-home-haemodialysis-mp9h6b08 2026-05-31 weekly 0.6 https://asnrt.org/news/potassium-disorders-hypokalemia-and-hyperkalemia-mq99ethz 2026-06-11 weekly 0.7 https://asnrt.org/ar/news/potassium-disorders-hypokalemia-and-hyperkalemia-mq99ethz 2026-06-11 weekly 0.6 https://asnrt.org/news/a-prespecified-exploratory-analysis-from-fidelity-examined-finerenone-use-and-kidney-outcomes-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-moi580to 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/a-prespecified-exploratory-analysis-from-fidelity-examined-finerenone-use-and-kidney-outcomes-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-moi580to 2026-05-31 weekly 0.6 https://asnrt.org/news/anti-glomerular-basement-membrane-vasculitis-mpw2pwhn 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/anti-glomerular-basement-membrane-vasculitis-mpw2pwhn 2026-07-05 weekly 0.6 https://asnrt.org/news/impact-of-diabetes-on-the-effects-of-sglt2-inhibitors-on-kidney-outcomes-collaborative-meta-analysis-of-large-placebo-controlled-trials-mppctulf 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/impact-of-diabetes-on-the-effects-of-sglt2-inhibitors-on-kidney-outcomes-collaborative-meta-analysis-of-large-placebo-controlled-trials-mppctulf 2026-05-31 weekly 0.6 https://asnrt.org/news/network-meta-analysis-of-finerenone-versus-sglt2-inhibitors-and-glp-1-receptor-agonists-on-cardiovascular-and-renal-outcomes-in-type-2-diabetes-and-chronic-kidney-disease-mppcpn94 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/network-meta-analysis-of-finerenone-versus-sglt2-inhibitors-and-glp-1-receptor-agonists-on-cardiovascular-and-renal-outcomes-in-type-2-diabetes-and-chronic-kidney-disease-mppcpn94 2026-05-31 weekly 0.6 https://asnrt.org/news/kdigo-diabetes-management-in-ckd-guideline-2024-mo858o2y 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/kdigo-diabetes-management-in-ckd-guideline-2024-mo858o2y 2026-05-31 weekly 0.6 https://asnrt.org/news/effects-of-tirzepatide-versus-insulin-glargine-on-kidney-outcomes-in-type-2-diabetes-in-the-surpass-4-trial-post-hoc-analysis-of-an-open-label-randomised-phase-3-trial-mpzd9nt7 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/effects-of-tirzepatide-versus-insulin-glargine-on-kidney-outcomes-in-type-2-diabetes-in-the-surpass-4-trial-post-hoc-analysis-of-an-open-label-randomised-phase-3-trial-mpzd9nt7 2026-06-08 weekly 0.6 https://asnrt.org/news/kdigo-clinical-practice-guideline-on-diabetes-management-in-chronic-kidney-disease-mnrbfdiv 2026-05-28 weekly 0.7 https://asnrt.org/ar/news/kdigo-clinical-practice-guideline-on-diabetes-management-in-chronic-kidney-disease-mnrbfdiv 2026-05-28 weekly 0.6 https://asnrt.org/news/novel-treatment-paradigms-focal-segmental-glomerulosclerosis-mozejcs4 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/novel-treatment-paradigms-focal-segmental-glomerulosclerosis-mozejcs4 2026-05-31 weekly 0.6 https://asnrt.org/news/european-guideline-for-the-management-of-kidney-transplant-patients-with-hla-antibodies-esot-working-group-mppc6ub1 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/european-guideline-for-the-management-of-kidney-transplant-patients-with-hla-antibodies-esot-working-group-mppc6ub1 2026-05-31 weekly 0.6 https://asnrt.org/news/xenotransplantation-of-porcine-kidneys-in-brain-dead-humans-mnqwruvt 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/xenotransplantation-of-porcine-kidneys-in-brain-dead-humans-mnqwruvt 2026-05-31 weekly 0.6 https://asnrt.org/news/roxadustat-versus-epoetin-alfa-for-treating-anemia-in-patients-with-chronic-kidney-disease-on-dialysis-results-from-the-randomized-phase-3-rockies-study-mra3f31i 2026-07-07 weekly 0.7 https://asnrt.org/ar/news/roxadustat-versus-epoetin-alfa-for-treating-anemia-in-patients-with-chronic-kidney-disease-on-dialysis-results-from-the-randomized-phase-3-rockies-study-mra3f31i 2026-07-07 weekly 0.6 https://asnrt.org/news/daprodustat-for-the-treatment-of-anemia-in-patients-undergoing-dialysis-mppc1vcf 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/daprodustat-for-the-treatment-of-anemia-in-patients-undergoing-dialysis-mppc1vcf 2026-05-31 weekly 0.6 https://asnrt.org/news/conversion-from-calcineurin-inhibitor--to-belatacept-based-maintenance-immunosuppression-in-renal-transplant-recipients-a-randomized-phase-3b-trial-mppcvcq3 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/conversion-from-calcineurin-inhibitor--to-belatacept-based-maintenance-immunosuppression-in-renal-transplant-recipients-a-randomized-phase-3b-trial-mppcvcq3 2026-05-31 weekly 0.6 https://asnrt.org/news/recurrent-glomerular-disease-after-kidney-transplantation-diagnostic-and-management-dilemmas-mptc1nwl 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/recurrent-glomerular-disease-after-kidney-transplantation-diagnostic-and-management-dilemmas-mptc1nwl 2026-05-31 weekly 0.6 https://asnrt.org/news/acute-kidney-injury-in-patients-treated-with-immune-checkpoint-inhibitors-mptbw125 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/acute-kidney-injury-in-patients-treated-with-immune-checkpoint-inhibitors-mptbw125 2026-07-05 weekly 0.6 https://asnrt.org/news/nice-guideline-ng247-ckd-mnqk6og9 2026-05-27 weekly 0.7 https://asnrt.org/news/prevention-of-cardiac-surgery-associated-acute-kidney-injury-by-implementing-the-kdigo-guidelines-in-high-risk-patients-identified-by-biomarkers-the-prevaki-multicenter-randomized-controlled-trial-mpw2v0xb 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/prevention-of-cardiac-surgery-associated-acute-kidney-injury-by-implementing-the-kdigo-guidelines-in-high-risk-patients-identified-by-biomarkers-the-prevaki-multicenter-randomized-controlled-trial-mpw2v0xb 2026-06-08 weekly 0.6 https://asnrt.org/news/imlifidase-desensitization-in-crossmatch-positive-highly-sensitized-kidney-transplant-recipients-results-of-an-international-phase-2-trial-highdes-mppc5sa7 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/imlifidase-desensitization-in-crossmatch-positive-highly-sensitized-kidney-transplant-recipients-results-of-an-international-phase-2-trial-highdes-mppc5sa7 2026-05-31 weekly 0.6 https://asnrt.org/news/recurrence-of-iga-nephropathy-after-kidney-transplantation-in-adults-mptc1x0b 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/recurrence-of-iga-nephropathy-after-kidney-transplantation-in-adults-mptc1x0b 2026-05-31 weekly 0.6 https://asnrt.org/news/efficacy-and-safety-of-voclosporin-versus-placebo-for-lupus-nephritis-aurora-1-a-double-blind-randomised-multicentre-placebo-controlled-phase-3-trial-mppc3fux 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/efficacy-and-safety-of-voclosporin-versus-placebo-for-lupus-nephritis-aurora-1-a-double-blind-randomised-multicentre-placebo-controlled-phase-3-trial-mppc3fux 2026-05-31 weekly 0.6 https://asnrt.org/news/safety-and-efficacy-of-vadadustat-for-anemia-in-patients-undergoing-dialysis-mpzd8t8f 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/safety-and-efficacy-of-vadadustat-for-anemia-in-patients-undergoing-dialysis-mpzd8t8f 2026-07-05 weekly 0.6 https://asnrt.org/news/a-randomized-clinical-trial-of-anti-il-6-antibody-clazakizumab-in-late-antibody-mediated-kidney-transplant-rejection-mq62mtu0 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/a-randomized-clinical-trial-of-anti-il-6-antibody-clazakizumab-in-late-antibody-mediated-kidney-transplant-rejection-mq62mtu0 2026-06-09 weekly 0.6 https://asnrt.org/news/avacopan-for-the-treatment-of-anca-associated-vasculitis-mppc2ad1 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/avacopan-for-the-treatment-of-anca-associated-vasculitis-mppc2ad1 2026-05-31 weekly 0.6 https://asnrt.org/news/propensity-score-matched-mortality-comparisons-of-peritoneal-and-in-centre-haemodialysis-systematic-review-and-meta-analysis-mq62rgo7 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/propensity-score-matched-mortality-comparisons-of-peritoneal-and-in-centre-haemodialysis-systematic-review-and-meta-analysis-mq62rgo7 2026-06-09 weekly 0.6 https://asnrt.org/news/a-systematic-review-of-immune-checkpoint-inhibitorassociated-glomerular-disease-mptbvcyi 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/a-systematic-review-of-immune-checkpoint-inhibitorassociated-glomerular-disease-mptbvcyi 2026-05-31 weekly 0.6 https://asnrt.org/news/two-year-randomized-controlled-trial-of-belimumab-in-lupus-nephritis-mppc33jy 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/two-year-randomized-controlled-trial-of-belimumab-in-lupus-nephritis-mppc33jy 2026-05-31 weekly 0.6 https://asnrt.org/news/home-hemodialysis-and-peritoneal-dialysis-patient-and-technique-survival-in-canada-mq62p978 2026-06-09 weekly 0.7 https://asnrt.org/ar/news/home-hemodialysis-and-peritoneal-dialysis-patient-and-technique-survival-in-canada-mq62p978 2026-06-09 weekly 0.6 https://asnrt.org/news/torque-teno-virus-for-risk-stratification-of-graft-rejection-and-infection-in-kidney-transplant-recipients---a-prospective-observational-trial-mq37nutu 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/torque-teno-virus-for-risk-stratification-of-graft-rejection-and-infection-in-kidney-transplant-recipients---a-prospective-observational-trial-mq37nutu 2026-06-08 weekly 0.6 https://asnrt.org/news/regulatory-cell-therapy-in-kidney-transplantation-the-one-study-a-harmonised-design-and-analysis-of-seven-non-randomised-single-arm-phase-12a-trials-mq37ocvd 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/regulatory-cell-therapy-in-kidney-transplantation-the-one-study-a-harmonised-design-and-analysis-of-seven-non-randomised-single-arm-phase-12a-trials-mq37ocvd 2026-06-08 weekly 0.6 https://asnrt.org/news/rituximab-or-cyclosporine-in-the-treatment-of-membranous-nephropathy-mppc1irb 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/rituximab-or-cyclosporine-in-the-treatment-of-membranous-nephropathy-mppc1irb 2026-05-31 weekly 0.6 https://asnrt.org/news/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy-credence-mppcu6vl 2026-07-05 weekly 0.7 https://asnrt.org/ar/news/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy-credence-mppcu6vl 2026-07-05 weekly 0.6 https://asnrt.org/news/sodium-zirconium-cyclosilicate-among-individuals-with-hyperkalemia-a-12-month-phase-3-study-mpw2qe4g 2026-06-08 weekly 0.7 https://asnrt.org/ar/news/sodium-zirconium-cyclosilicate-among-individuals-with-hyperkalemia-a-12-month-phase-3-study-mpw2qe4g 2026-06-08 weekly 0.6 https://asnrt.org/news/home-hemodialysis-and-patient-reported-outcomes-mnrbhcbb 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/home-hemodialysis-and-patient-reported-outcomes-mnrbhcbb 2026-05-31 weekly 0.6 https://asnrt.org/news/tolvaptan-in-later-stage-autosomal-dominant-polycystic-kidney-disease-mppc2p6k 2026-05-31 weekly 0.7 https://asnrt.org/ar/news/tolvaptan-in-later-stage-autosomal-dominant-polycystic-kidney-disease-mppc2p6k 2026-05-31 weekly 0.6 https://asnrt.org/education/patient/transplant/kidney-failure-overview 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/kidney-failure-overview 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/end-stage-disease 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/end-stage-disease 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/dialysis 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/dialysis 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/transplant-overview 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/transplant-overview 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/surgery 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/surgery 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/immunosuppressants 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/immunosuppressants 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/infection-prevention 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/infection-prevention 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/vaccination 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/vaccination 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/diet 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/diet 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/activities 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/activities 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/follow-up 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/follow-up 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/labs-imaging 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/labs-imaging 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/complications 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/complications 2026-05-21 monthly 0.7 https://asnrt.org/education/patient/transplant/marriage-pregnancy 2026-05-21 monthly 0.7 https://asnrt.org/ar/education/patient/transplant/marriage-pregnancy 2026-05-21 monthly 0.7 https://asnrt.org/journal/8/2 2026-06-30 yearly 0.7 https://asnrt.org/journal/8/1 2026-05-06 yearly 0.7 https://asnrt.org/journal/7/2 2026-05-10 yearly 0.7 https://asnrt.org/journal/7/1 2026-05-10 yearly 0.7 https://asnrt.org/journal/6/3 2026-05-10 yearly 0.7 https://asnrt.org/journal/6/2 2026-05-10 yearly 0.7 https://asnrt.org/journal/6/1 2026-05-10 yearly 0.7 https://asnrt.org/journal/5/3 2026-05-10 yearly 0.7 https://asnrt.org/journal/5/2 2026-05-10 yearly 0.7 https://asnrt.org/journal/5/1 2026-05-10 yearly 0.7 https://asnrt.org/journal/4/3 2026-05-10 yearly 0.7 https://asnrt.org/journal/4/1 2026-05-10 yearly 0.7 https://asnrt.org/journal/3/3 2026-05-10 yearly 0.7 https://asnrt.org/journal/3/2 2026-05-10 yearly 0.7 https://asnrt.org/journal/3/1 2026-05-10 yearly 0.7 https://asnrt.org/journal/2/3 2026-05-10 yearly 0.7 https://asnrt.org/journal/2/2 2026-05-10 yearly 0.7 https://asnrt.org/journal/2/1 2026-05-10 yearly 0.7 https://asnrt.org/journal/1/1 2026-05-10 yearly 0.7 https://asnrt.org/journal/8/2/renal-educator-role-and-responsibilities-and-applicability-in-arab-countries 2026-06-30 yearly 0.6 https://asnrt.org/journal/8/2/senescence-associated-secretory-phenotype-and-accelerated-renal-aging-in-chronic 2026-06-30 yearly 0.6 https://asnrt.org/journal/8/2/depression-in-chronic-hemodialysis-patients-screening-and-associated-factors-on- 2026-06-30 yearly 0.6 https://asnrt.org/journal/8/2/impact-of-flood-disaster-on-dialysis-care-in-maiduguri-northeastern-nigeria 2026-06-30 yearly 0.6 https://asnrt.org/journal/8/2/immune-complex-membranoproliferative-glomerulonephritis-in-a-kidney-transplant-r 2026-06-30 yearly 0.6 https://asnrt.org/journal/8/1/microplastic-exposure-and-kidney-disease-an-emerging-environmental-nephrotoxin-i 2026-05-06 yearly 0.6 https://asnrt.org/journal/8/1/artificial-intelligence-enhanced-vascular-access-in-hemodialysis-challenges-and- 2026-05-06 yearly 0.6 https://asnrt.org/journal/8/1/acute-kidney-injury-is-a-major-risk-in-coronavirus-disease-2019-infected-patient 2026-05-06 yearly 0.6 https://asnrt.org/journal/8/1/conservative-management-of-hemodialysis-catheter-related-infections-feasibility- 2026-05-06 yearly 0.6 https://asnrt.org/journal/8/1/focal-segmental-glomerulosclerosis-prevalence-risk-factors-and-outcome-among-kid 2026-05-06 yearly 0.6 https://asnrt.org/journal/7/2/cardiovascular-manifestations-of-allograft-dysfunction-in-renal-transplant-recip 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/uremic-pruritus-pathogenesis-revisited 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/the-diagnostic-value-of-detection-of-cd20-positive-infiltrates-in-renal-biopsies 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/prognosis-of-acute-post-streptococcal-glomerulonephritis-in-sudanese-children 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/emphysematous-pyelonephritis-in-a-diabetic-patient-on-maintenance-hemodialysis-a 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/re-eximination-of-renal-allograft-biopsy-blocks-for-c4d-positivity-missed-cases- 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/clinical-presentation-and-management-outcome-of-childhood-onset-systemic-lupus-e 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/the-clinical-pattern-of-primary-hyperoxaluria-in-pediatric-at-queen-rania-abdull 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/social-aspects-of-kidney-donation-in-tunisia-a-study-of-189-living-related-donor 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/2/prevalence-of-seroconversion-of-hepatitis-c-virus-among-hemodialysis-patients-in 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/management-of-anemia-and-other-hematologic-derangements-in-patients-with-chronic 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/histopathological-association-between-vascular-hypertensive-changes-and-differen 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/experience-in-using-thermal-disinfection-to-remove-viable-bacteria-and-endotoxin 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/pelvi-ureteric-junction-obstruction-at-red-cross-children-s-hospital-cape-town-a 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/lupus-nephritis-emerging-during-remission-of-minimal-change-disease 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/acute-pancreatitis-a-rare-complication-in-a-patient-with-senior-loken-syndrome 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/prevalence-and-risk-factors-of-central-venous-stenosis-among-prevalent-hemodialy 2026-04-27 yearly 0.6 https://asnrt.org/journal/7/1/pattern-of-renal-diseases-among-children-in-the-niger-delta-region-nigeria 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/dense-deposit-disease-a-29-years-electron-microscopy-experience 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/the-spectrum-of-glomerular-diseases-as-studied-by-immunofluorescence-microscopy- 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/acupuncture-efficacy-in-the-treatment-of-persistent-primary-nocturnal-enuresis 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/acute-tubulo-interstitial-nephritis-with-positive-anti-neutrophil-cytoplasmic-an 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/depression-in-iraqi-hemodialysis-patients 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/idiopathic-membranous-nephropathy-preceding-the-onset-of-rheumatoid-arthritis-a- 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/nephrogenic-diabetes-insipidus-with-intracranial-calcifications-in-a-child-with- 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/prevalence-of-non-communicable-diseases-and-its-awareness-among-inhabitants-of-s 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/3/a-preliminary-survey-of-un-diagnosed-hypertension-among-nubians-and-coptics-in-a 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/2/acute-kidney-injury-global-health-alert 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/2/type-1-type-2-cytokine-serum-levels-and-role-of-interleukin-18-in-children-with- 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/2/parameters-to-assess-nutritional-status-in-a-moroccan-hemodialysis-cohort 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/2/adherence-of-healthcare-professionals-to-evidence-based-clinical-practice-guidel 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/2/epidemiology-and-clinicopathologic-outcome-of-pediatric-chronic-kidney-disease-i 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/2/severe-tricuspid-valve-endocarditis-related-to-tunneled-catheters-in-chronic-hem 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/2/evaluation-of-nurses-awareness-and-practice-of-hemodialysis-access-care-in-khart 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/editorial-hypertension-new-data-and-implications 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/negative-correlation-between-fetuin-a-and-indices-of-vascular-disease-in-systemi 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/case-report-anca-negative-pulmonary-renal-syndrome-with-pathologic-findings-of-t 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/case-report-gitelman-syndrome-as-a-cause-of-psychomotor-retardation-in-a-toddler 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/urinary-albumin-and-interleukin-8-levels-are-not-good-indicators-of-ongoing-vesi 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/case-report-treatment-of-hepatitis-b-virus-reactivation-in-a-cadaveric-renal-tra 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/chronic-renal-allograft-dysfunction-risk-factors-immunology-and-prevention 2026-04-27 yearly 0.6 https://asnrt.org/journal/6/1/the-potential-role-of-nursing-students-in-the-implementation-of-community-based- 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/editorial-reducing-the-cost-of-renal-transplantation-in-developing-countries 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/applying-sodium-profile-with-or-without-ultrafiltration-profile-failed-to-show-b 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/active-tuberculous-infection-among-adult-sudanese-patients-on-long-term-peritone 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/prevalence-of-the-metabolic-syndrome-in-renal-transplant-recipients 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/prevalence-of-hcv-infections-among-hemodialysis-patients-in-al-gharbiyah-governo 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/rheumatic-heart-disease-associated-with-secondary-renal-amyloidosis 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/scleroderma-renal-crisis-precipitated-by-steroid-treatment-in-systemic-lupus-ery 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/acute-renal-failure-following-the-saharan-horned-viper-cerastes-cerastes-bite 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/3/posterior-reversible-encephalopathy-syndrome-in-a-child-with-steroid-sensitive-n 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/2/editorial-the-ethical-aspects-of-medical-research 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/2/reaching-target-hemoglobin-level-and-having-a-functioning-arteriovenous-fistula- 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/2/clinical-course-of-acute-pancreatitis-in-chronic-kidney-disease-patients-in-a-si 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/2/the-pattern-of-histologically-proven-acute-post-infectious-glomerulonephritis-in 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/2/informed-consent-for-inclusion-into-clinical-trials-a-serious-subject-to-note-in 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/2/thrombotic-thrombocytopenic-purpura-and-systemic-lupus-erythematosus-a-rare-and- 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/2/crossed-renal-ectopia-coexisting-with-nephrolithiasis-in-a-young-nigerian-man 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/1/glucocorticoid-receptors-and-the-pattern-of-steroid-response-in-idiopathic-nephr 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/1/delayed-graft-function-allograft-and-patient-survival-in-kidney-transplantation 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/1/soluble-tweak-and-cardiovascular-morbidity-and-mortality-in-chronic-kidney-disea 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/1/aminophylline-improves-urine-flow-rates-but-not-survival-in-childhood-oliguric-a 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/1/renal-transplantation-and-pregnancy 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/1/bradycardia-following-oral-corticosteroid-use-case-report-and-literature-review 2026-04-27 yearly 0.6 https://asnrt.org/journal/5/1/short-term-use-of-cinacalcet-in-children-on-regular-hemodialysis 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/hepatic-lymphomas-post-renal-transplantation-may-signify-worse-disease-behavior- 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/chemokine-and-chemokine-receptor-gene-polymorphism-in-tunisian-hemodialysis-pati 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/a-study-of-quality-of-life-and-its-determinants-among-hemodialysis-patients-usin 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/serum-leptin-and-bone-mineral-density-in-hemodialysis-patients-with-or-without-l 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/histopathological-study-of-pure-primary-nephrotic-syndrome-in-adolescents-and-yo 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/undiagnosed-hypertension-and-proteinuria-in-a-market-population-in-ile-ife-niger 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/management-of-pediatric-tumor-lysis-syndrome 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/high-ureteric-injury-following-multiorgan-recovery-successful-kidney-transplant- 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/3/systemic-lupus-erythematosus-with-severe-nephritis-that-mimicked-henoch-schoenle 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/1/staff-knowledge-adherence-to-infection-control-recommendations-and-seroconversio 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/1/the-association-between-prolonged-occupational-exposure-to-paraphenylenediamine- 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/1/non-infectious-complications-of-peritoneal-dialysis-among-sudanese-patients-five 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/1/case-report-castleman-s-disease-in-a-kidney-failure-patient-diagnosed-incidental 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/1/prevention-of-hepatitis-b-virus-and-hepatitis-c-virus-transmission-in-hemodialys 2026-04-27 yearly 0.6 https://asnrt.org/journal/4/1/case-presentation-regression-of-kaposi-s-sarcoma-in-a-sudanese-kidney-transplant 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/3/natural-history-of-chronic-kidney-disease-stages-2-4 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/3/association-between-low-adiponectin-level-and-cardiovascular-complications-in-di 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/3/emergence-and-progression-of-albuminuria-in-a-cohort-of-egyptian-patients-with-t 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/3/bone-activity-biomarkers-and-bone-mineral-density-in-children-with-chronic-kidne 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/3/recurrent-transvaginal-leak-of-dialysate-as-a-complication-of-peritoneal-dialysi 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/3/the-history-of-nephrology-in-tunisia 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/natural-history-of-progression-of-chronic-kidney-disease-in-stages-4-and-5 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/short-term-outcome-of-coronary-artery-bypass-grafting-in-patients-receiving-hemo 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/impact-of-cytotoxin-associated-gene-product-a-positive-helicobacter-pylori-strai 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/nephropathy-and-neuropathy-in-diabetic-patients-with-chronic-hepatitis-c-virus-i 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/renal-replacement-therapy-in-sudan-2009 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/therapeutic-potential-of-25-hydroxyvitamin-d-in-promoting-cardiovascular-health 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/outbreak-of-peritonitis-in-a-continuous-ambulatory-peritoneal-dialysis-populatio 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/2/urinary-tract-infection-in-renal-transplant-recipients 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/1/evaluation-of-peripheral-vascular-calcification-and-serum-magnesium-level-in-a-g 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/1/dyslipidemia-among-sudanese-children-undergoing-maintenance-dialysis 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/1/comparison-between-doppler-ultrasound-and-biopsy-findings-in-patients-with-suspe 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/1/the-effect-of-ramadan-fasting-on-the-kidney-function-of-renal-transplant-recipie 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/1/correlation-between-tumor-necrosis-factor-alpha-and-proteinuria-in-type-2-diabet 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/1/case-series-calciphylaxis-do-calcimimetics-have-a-role-in-management 2026-04-27 yearly 0.6 https://asnrt.org/journal/3/1/review-paraphenylene-diamine-hair-dye-poisoning-in-children 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/3/the-effect-of-mild-preoperative-renal-impairment-on-early-postoperative-mortalit 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/3/t-helper-1-immune-response-in-systemic-lupus-erythematosus-and-its-relation-to-d 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/3/low-incidence-of-contrast-induced-nephropathy-after-coronary-angiography-in-pati 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/3/evidence-to-support-a-putative-role-for-insulin-resistance-in-chronic-kidney-dis 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/3/could-uric-acid-have-a-pathogenic-role-in-chronic-allograft-dysfunction 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/3/reversible-posterior-leukoencephalopathy-syndrome-preceding-end-stage-renal-fail 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/2/acute-urinary-tract-infections-in-children-in-khartoum-state-pathogens-antimicro 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/2/technetium-99m-sestamibi-scintigraphy-pattern-in-patients-with-secondary-hyperpa 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/2/chronic-kidney-disease-in-police-forces-households-in-khartoum-sudan-pilot-repor 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/2/progress-on-autosomal-dominant-polycystic-kidney-disease 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/2/six-cases-of-fungal-peritonitis-complicating-peritoneal-dialysis-in-a-single-cen 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/2/isolated-renal-sarcoidosis-a-rare-cause-for-granulomatous-interstitial-nephritis 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/2/successful-conservative-management-of-scrotal-edema-resulting-from-uncomplicated 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/1/five-years-survival-on-hemodialysis-predicted-by-artificial-neural-network-model 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/1/the-sudan-peritoneal-dialysis-program-three-years-of-momentum 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/1/management-of-renovascular-disease 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/1/protocol-for-management-of-peritoneal-dialysis-related-infections-in-sudan 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/1/restoration-of-kidney-function-after-prolonged-four-months-anuria-due-to-bilater 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/1/tackling-fluid-overload-in-a-high-transporter-diabetic-patient-on-continuous-amb 2026-04-27 yearly 0.6 https://asnrt.org/journal/2/1/multiple-hemodialysis-access-failures-due-to-recurrent-thrombosis-in-a-patient-w 2026-04-27 yearly 0.6 https://asnrt.org/journal/1/1/renal-replacement-therapy-resources-in-africa 2026-04-27 yearly 0.6 https://asnrt.org/journal/1/1/what-clinical-and-laboratory-parameters-distinguish-between-acute-and-chronic-re 2026-04-27 yearly 0.6 https://asnrt.org/journal/1/1/post-transplant-diabetes-mellitus-in-ahmed-gasim-kidney-transplant-center-sudan 2026-04-27 yearly 0.6 https://asnrt.org/journal/1/1/encysted-fluid-collections-after-catheter-removal-for-peritonitis-in-peritoneal- 2026-04-26 yearly 0.6 https://asnrt.org/journal/1/1/a-personal-reflection-on-the-history-of-renal-medicine-in-the-sudan 2026-04-26 yearly 0.6 https://asnrt.org/journal/1/1/rapidly-progressive-iga-nephropathy-in-one-of-a-pair-of-identical-twins 2026-04-26 yearly 0.6